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Mechanisms of Erythropoietin-induced Neuroprotection in: in-vivo and 
in-vitro Models of Hypoxia Ischemia 
by 
Rhonda Andrea Souvenir 
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics  
Loma Linda University, December 2011 
Dr. Jiping Tang, Chairperson 
 
Hypoxic ischemic brain injury (HIBI) is a common cause of neonatal mortality and 
morbidity.  Approximately 60 % of preterm babies and 2% of full term infants suffer from 
asphyxia. Asphyxia related death accounts for approximately 23% of neonatal mortality 
annually. Many therapeutic interventions show promise in the laboratory but fail in 
clinics. A thorough understanding of mechanisms by which promising therapeutic 
intervention confers its neuroprotection is necessary to promote smoother transitions 
from bench to the bedside. Erythropoietin (EPO), a hematopoietic growth factor that 
increases oxygen availability during hypoxia/ischemia is associated with cell survival and 
neuroprotection in: in vivo and in vitro models of hypoxia ischemia. However these 
studies hold limited clinical translations because the underlying mechanism remains 
unclear and the key molecules involved in EPO-induced neuroprotection are still to be 
determined.  Thus the central aim of this proposal is: to determine the key 
mediators of EPO-induced neuroprotection and the mechanisms by which this 
occurs in: in vitro and in vivo models of hypoxia ischemia.   
Two alternate pathways of EPO-induced neuroprotection were elucidated in vitro 
using oxygen and glucose deprivation to mimic hypoxia ischemia. Our findings showed 
that EPO treatment resulted in an upregulation of tissues inhibitor of matrix 
metalloproteinase (TIMP)-1 and inhibition of hypoxia inducible factor (HIF-1) both of 
xiii 
which subsequently decreased in matrix metalloproteinase (MMP)-9 and promoted 
neuroprotection.  MMP-9 inhibition was associated with neuroprotection in both 
pathways thus, inferring that inhibition of MMP-9 is one of the primary mechanisms of 
EPO-induced neuroprotection. We also observed that EPO-induced neuroprotection was 
reversed by inhibition of TIMP-1 or prolyl hydroxylase (PHD)-2. This lends to the 
conclusion that TIMP-1 and PHD-2 are the key mediators of EPO-induced 
neuroprotection in: in vivo and in vitro models of hypoxia ischemia.  
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CRITICAL NON-HEMATOPOIETIC FUNCTIONS OF ERYTHROPOIETIN IN 
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Note: Most of this chapter is taken from a review paper currently in the submission 
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Abstract 
Stroke continues to be one of the leading causes of mortality and morbidity 
nationwide with only few therapeutic options. Recombinant human erythropoietin 
(rhEPO) showed promising results in animal studies, and in human neonates. However 
rhEPO treatment proved to be ineffective and sometimes detrimental against 
subarachnoid or ischemic stroke in adults. The purpose of this review was to elucidate 
the critical non-hematopoietic function of EPO-induced neuroprotection in the different 
stroke models. Major biomedical bibliographical databases (MEDLINE, ISI, and 
Cochrane Library) were searched with use of major keywords such as erythropoietin, 
stroke, neonatal hypoxia ischemia and multiple terms denoting components of EPO 
signaling pathways. EPO activates common signaling pathways for both hematopoietic 
and non hematopoietic functions. However, there are important distinctions in the 
molecular mechanisms of EPO-induced neuroprotection depending upon the level of 
EPOR expression, injury type and developmental stage of affected individuals.  Both 
high dose EPO treatment and long term therapy tends to initiate notable erythropoiesis, 
coagulation and thrombosis. Thus in order to harness the beneficial non-hematopoietic 
functions of EPO in stroke therapy, the dose and duration of EPO treatment needs to be 
carefully optimized and potential side effects closely monitored.  
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Introduction 
Stroke is the altering of brain, blood supply either by the rupturing or obstruction 
of a vessel (WHO). The manner in which the blood supply is interrupted determines if 
the stroke is hemorrhagic or ischemic. Hemorrhagic strokes are less common but more 
detrimental than ischemic strokes. Alternately, a hemorrhagic stroke could lead to an 
ischemic stroke (ASA; WHO).  Thus, we’ll focus primarily on cerebral ischemia. There 
are two main categories of stroke: ischemia and hemorrhage can be further categorized 
according to the region of the brain affected.  Subarachnoid hemorrhage (SAH), 
intracerebral hemorrhage (ICH), global ischemia, focal ischemia, neonatal hypoxia 
ischemia are all modeled in laboratory animals and was shown to be attenuated by 
erythropoietin treatment. Systemic administration of  single or multiple doses of 
recombinant Erythropoietin (EPO) pre- or post- insult was shown to confer 
neuroprotection in subarachnoid hemorrhage (Alafaci et al., 2000; Grasso, 2001; Grasso 
et al., 2002a; Grasso, 2004), intracerebral hemorrhage (Lee et al., 2006d; Grasso et al., 
2009b), global ischemia ((Sakanaka et al., 1998; Calapai et al., 2000; Catania et al., 
2002), focal ischemia (Bernaudin et al., 1999; Brines et al., 2000; Zhang et al., 2010a), 
neonatal hypoxia-ischemia (Kumral et al., 2004; Kumral et al., 2003), tramautic brain 
injury (Lu et al., 2005; Chen et al., 2007) and even spinal cord injury (Gorio et al., 2002) , 
Parkinson’s (Kanaan et al., 2006) and multiple sclerosis (Sattler et al., 2004). Thus, EPO 
was hailed as the panacea in stroke therapy and rapidly advanced to clinical trials. 
 Clinical trials for the use of EPO in SAH treatment yielded inconclusive results 
due to a small population size; but showed promising results in Phase I for the treatment 
of neonatal HI and adult cerebral ischemia (Meyer et al., 2003). These findings served to 
bolster confidence in EPO’s potential for stroke therapy and accelerated its advance into 
Phase II clinical trial (McPherson & Juul, 2010b) Hence, it was a resounding blow to 
EPO researchers and the stroke community at large when Ehrenreich and colleagues 
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reported that EPO not only failed to improve injury but also promoted tumor formation 
and reduced quality of life for stroke patients in a multicenter clinical trial (Ehrenreich et 
al., 2009). The failure of EPO in Phase II/III clinical trials raised several questions: Was 
the route of administration too traumatic? Was the potential seen in animal models 
exaggerated? Were the proposed mechanisms of action not clear? Or is EPO, like its 
primary regulator HIF-1 a biphasic molecule, that is beneficial or detrimental depending 
on the dose and time of administration? EPO has been administered intravenously for 
treatment of anemia over the past ten years with no major complication. Additionally 
Taylor and colleagues showed that there were no difference in the prevalence of 
thrombotic and hypertensive side between patients administered EPO intravenously 
compared to subcutaneously (Taylor et al., 1994). Thus if the route of administration 
affected the outcome it would have played a minor role in EPO’s failure in Phase II/III 
clinical trial. A comprehensive review of EPO treatment in animal models of stroke with 
Meta analysis still predicts that EPO should show positive result in stroke therapy 
(Jerndal et al., 2010; Minnerup et al., 2009). Since two of the four critical questions were 
previously answered we’ll focus on the critical non hematopoietic function of EPO and 
the mechanisms by which EPO accomplishes these functions. 
 
Hypoxia Ischemia  
Cerebral ischemia is associated with impaired cerebral blood flow (CBF), skewed 
pH and electrolyte balance and increased free radical formation, intracranial pressure 
(ICP) and inflammation (Dearden, 1985). Reduced CBF limits energy availability and 
forces the cell into anaerobic respiration, which creates an acidic environment and 
shifting in the sodium, potassium, calcium equilibrium (Siesjo et al., 1985a; Siesjo et al., 
1985b). Hypoxia is the physiological point at which the demand for oxygen supersedes 
the available oxygen supply thus forces the body/cells to drastically alter its O2 
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expenditure. Hypoxia triggers anaerobic respiration which results in an increase in 
acidity.  Low oxygen or acidic environment results in an accumulation of HIF-1 in the 
cytoplasm (Jelkmann, 2005; Semenza, 2000b; Semenza, 2000a).  
 
Erythropoietin Regulation 
Cerebral hypoxia ischemia promotes an accumulation of hypoxia inducible factor 
1 (HIF)-1 in neurons. HIF-1 has over 70 targets genes most of which are up-regulated 
in response to hypoxia (Zagorska & Dulak, 2004).HIF-1 downstream gene EPO is 
upregulated during ischemia in the brain of most mammals (Prass et al., 2003a). The 
expression of EPO and EPO-receptor (EPOR) is regulated by HIF. HIFs are 
heterodimeric transcription factors consisting of alpha and beta subunits (Chandel et al., 
2000). HIF-1 and-2 shares 40% homology.HIF-2 has been shown to bind to the beta 
subunit of HIF1 during hypoxia (Krieg et al., 2000). An accumulation of HIF-1 or HIF-
2 during hypoxia is tissue dependant.  The specific HIF in neuronal tissue is still highly 
debate. HIF-1 regulates both pro and anti-apoptotic genes. Thus it’s considered to be 
biphasic (Halterman & Federoff, 1999). Previous studies have suggest that the an 
accumulation of HIF-1 is beneficial in the up-regulation of vascular endothelial growth 
factor (VEGF) (Mu & Chang, 2003), EPO (Prass et al., 2003b), glucose transporter-1 
(GLUT-1), glycolytic enzymes (Jones & Bergeron, 2001). However the early increase in 
HIF-1alsolead to up-regulation of detrimental genes BNIP3(Bruick, 2003), Nix (Sowers 
et al., 2001), p53 and the caspases  (Li et al., 2005b). Our unpublished findings show 
that exogenous administration of EPO inhibits HIF-1 in a dose dependent manner. The 
mechanism by which this occurs warrants further studies. 
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Erythropoietin  
EPO is a hematopoietic growth factor that stimulates red blood cell (RBC) 
production and is released in response to low oxygen (Haroon et al., 2003; Siren et al., 
2001b; Siren et al., 2001a). EPO secretion switches from the liver in the fetus to the 
kidney in adults and is the primary regulator of erythropoiesis in mammals (Dame et al., 
2004). EPO is a part of the hypoxic response element and a known downstream gene of 
HIF-1. Under physiological conditions serum EPO levels ranges from 4-27 mU/mL 
(Caro & Erslev, 1988).  However during hypoxia ischemia or asphyxia associated 
condition there is more than a hundredth folds increase in serum EPO; this in turn 
increases circulating reticulocytes, oxygen carrying capacity of the blood and overall 
tissue oxygenation (Siren et al. 2001b; Siren et al. 2001a). In addition to hematopoietic 
tissue, EPOR expression was observed on ovarian (Masuda et al., 2000), testicular 
(Magnanti et al., 2001; Kobayashi et al., 2002), intestinal, pancreatic, cardiovascular (Wu 
et al., 1999c; Wu et al., 1999b; Wu et al., 1999a) and neuronal tissues (Liu et al., 1997; 
Tsai et al., 2006).  In addition to its hematopoietic functions EPO is also associated with 
cellular differentiation, proliferation and inhibition of apoptosis (Brines et al. 2000; 
Sakanaka et al. 1998; Sun et al., 2005). It prevents damage against mechanical trauma, 
excitotoxins, and neuro-inflammation (Brines et al. 2000; Sakanaka et al. 1998; Sun et 
al. 2005).Whether or not the non-hematopoietic functions of EPO are transmitted via the 
same receptor and signaling pathway as the hematopoietic functions is heavily debated. 
Casals-Pascual speculated that the erythroid functions are carried out via the 
homodimer form of the EPOR whereas cellular proliferation, survival and differentiation 
in non hematopoietic cells are carried out by the β-receptor subunit (βcR) which is a 
heterodimer (Casals-Pascual et al., 2009). A clear understanding of EPO signaling in 
hematopoietic and non-hematopoietic events is pertinent to the clinical future of EPO in 
stroke therapy. Should two different isoforms of EPOR be identified, the signaling 
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pathway still presents a challenge because the current dogma states that EPO signals 
via the Janus Kinase (JAK) -2 pathway and its downstream signaling pathway in both 
events.  
 
Signaling Pathways of Erythropoietin 
It is believed that binding of EPO to EPOR promotes the phosphorylation of 
receptor associated tyrosine kinase, JAK-2 (Lacombe & Mayeux, 1999; Constantinescu 
et al., 1999). Phosphorylated JAK-2, phosphorylates cytosolic transcription factor, signal 
transducers and activators of transcription (STAT) allowing for the transcription of 
proteins such as: cytokines, growth factors, cell survival and differentiation factors (Ihle, 
1995a; Ihle, 1995c; Shuai et al., 1992a; Kaplan & Di, 1996b).  
Janus Kinases are a family of receptor associated tyrosine kinases which 
phosphorylates the receptor it’s allied with (Ihle 1995a; Ihle 1995b).The specific receptor 
recruits different signaling molecules such as STAT proteins 1-6 for phosphorylation 
(Ihle, 1995b; Ihle, 1995d; Shuai et al., 1992b; Kaplan & Di, 1996a). The phosphorylated 
protein is translocated to the nucleus where it binds to the promoter of the specific gene 
and initiates transcription of that gene (Ihle 1995a; Ihle 1995b). Previous studies have 
shown that EPO and other hematopoietic growth factors are associated with the JAK-2 
tryosine kinase (Witthuhn et al., 1993). However, the specific STAT that is 
phosphorylated by each growth factor differs. STAT-3 is associated with EPOR  
activation (Kretz et al., 2005) whereas STAT-6 and STAT-4 are responds to interleukin 
(IL)-4 (Kaplan 1996a) and IL-12 (Kaplan 1996b) respectively. STAT-5 one of the most 
widely studies transcription factors is also associated with EPOR binding. Studies have 
shown that EPO activated STAT-5 promotes the transcription of anti apoptotic gene 
BCL-XL and activation of Ras mitogen activated protein kinase (MAPK), ERK-1/-2, and 
PI3K/Akt pathways (Kilic et al., 2005). STAT-3 is associated with propagation of growth 
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in mature neurons and cell survival (Cheng et al., 2011). Studies have shown that STAT-
3 binds to the promoter of sequences of TIMP-1, which is associated with cell survival, 
growth and differentiation in the presence of EPO (Kadri et al., 2000; Bugno et al., 1995) 
TIMPs are endogenous inhibitors of MMPs (Jiang et al., 2002; Baker et al., 
2002). They are a family of four secreted proteins (TIMPs 1-4) that function in 
maintaining extracellular matrix homeostasis (Gomez et al., 1997; Stetler-Stevenson et 
al., 1990). TIMP-1 and TIMP-2 are believed to promote cell proliferation and enhanced 
erythroid activity (Kadri et al., 2000). Subsequently TIMP-1 a 28.5-kDa glycoprotein was 
found to be regulated by EPO. EPO triggers an increase in both mRNA and protein 
levels of TIMP-1 (Kadri et al., 2000). TIMP-1 forms a 1:1 complex with MMP-9 and 
inhibits its proteinase activities. MMPs are a family of protein-degrading zinc dependant 
endopeptidases.  MMPs cleave most of the extracellular matrix (ECM) and are involved 
in the breakdown and remodeling of many tissues and organs (Isaksen & Fagerhol, 
2001; Szabova et al., 2005). Studies have shown an inverse correlation with MMP-9 
expression and activity and cell survival (Kadri et al., 2000). The same pathways utilized 
in hematopoietic cells via EPO to promote differentiation, maturation, and survivals of 
erythroid cells are utilized during EPO-induced neuroprotection. Thus EPO-induced cell 
survival is more dependent on EPOR expression that cell type.  
 
Erythropoietin and the Brain 
Endogenous EPO signaling has been studied in the development of the central 
nervous system and in neuroprotection.  Increased neuronal apoptosis was 
demonstrated in EPO-null and EPOR-null mice (Yu et al., 2001; Yu et al., 2002).  EPO 
has been regarded as an important regulator of the differentiation of neural progenitor 
cells (NPCs).  The importance of EPOR expression and activation to the neuroprotective 
effects of EPO has been demonstrated by Wang and colleagues (Wang et al., 2004; 
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Wang et al., 2006). EPOR expression on NPCs seems necessary for NPCs 
differentiation into mature neurons but less important in mature neurons.  EPOR-null 
mice exhibited significant lower levels of NPCs in the subventricular zone compared to 
the wild-type counterparts. Transgenic mice (EPOR-/-) were less resistant to hypoxia 
ischemia and exhibit defect in NPCs maturation and migration to the ischemic penumbra 
(Tsai et al., 2006). In addition to its role in NPCs differentiation, maturation and migration 
EPO and EPOR also play significant role in neuronal survival in the different stroke 
models (Studer et al., 2000; Shingo et al., 2001). 
 
Erythropoietin-induced Neuroprotection in-vitro 
In vitro studies have shown that EPO is neuroprotective in cultured hippocampal 
and cortical neurons against glutamate toxicity (Morishita et al., 1997), oxygen and 
glucose deprivation (OGD) (Sinor & Greenberg, 2000) and chemically induced hypoxia 
(Siren et al., 2001b). Primary neuronal cultures exposed to OGD were protected via 
EPO administration in a dose and time dependent manner. EPO induced 
neuroprotection in vitro was associated with suppression of Bad and upregulation of 
JAK-2, STAT-5, PI3K, AKT and Bcl2 (Ruscher et al., 2002). In addition to the anti-
apoptotic properties of EPO antioxidant properties were also detected in cultures. 
Studies have shown that EPO stabilizes mitochondrial membrane potential and 
decrease ROS in Abeta (25-35)-induced neuronal toxicity in PC-12 cells, up-regulated 
anti-apoptotic and down regulate pro-apoptotic proteins (Li et al., 2005a). The protective 
effects of EPO were not limited to in vitro findings. 
 
Erythropoietin-induced neuroprotection in Subarachanoid Hemorrhage 
Despite the difference in pathophysiology, EPO was shown to be neuroprotective 
in more than one animal models of hemorrhagic stroke. EPO was shown to reduce 
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neuronal damage and S-100 expression in cerebrospinal fluid of SAH rabbits 24, 48 and 
72 hours after insult.  Decrease S-100 was correlated with improved neurological 
outcome (Grasso et al., 2002). In a rat intracisternal blood injection SAH model,  a single 
low dose of EPO (400IU/Kg) was shown to improve mean arterial blood pressure and 
cerebral blood flow autoregulation (Springborg et al., 2003) . Increase in CSF, EPO 
expression, reduced neurological deficits, vasoconstriction and attenuation of 
vasospasm was observed in EPO treated SAH white rabbits (Grasso et al., 2002b). 
Previous studies have shown that EPO gene administration prompts an increase in 
phospho endothelial nitric oxide synthase (eNOS) and phospho-AKT with a 
corresponding decrease in eNOS. This finding infers that EPO confers neuroprotection 
and reduce vasospasm by modulating phosphorylated AKT and eNOS in SAH 
(Santhanam et al., 2005). Alternately it appears that the neuroprotective mechanism of 
EPO is conserved between models. 
 
Erythropoietin-induced neuroprotection in Intracerebral Hemorrhage 
Neuroprotection from collagenase induced ICH in rats by EPO was associated 
with reduced hematoma formation, edema, apoptosis and inflammation and improved 
neurological outcomes (Lee et al., 2006; Grasso et al., 2009). The dose and form of 
EPO did not appear to hamper its neuroprotective properties. Intraperitoneal 
administration of 500 to 5000IU/kg of recombinant human (rHu) EPO or 1000IU/kg 
Darbepoetin alfa conferred neuroprotection after ICH (Lee et al., 2006b; Grasso et al., 
2009a). The neuroprotection observed in ICH was correlated decrease caspase, 3, 8 
and 9 activity, TNF and Fas ligand expression (Lee et al., 2006a; Grasso et al., 2009c). 
There was also notable increase in STAT-3, pAkt , pERK  and eNOS activity observed in 
EPO treated ICH rats. This observation alludes to an overlap in the mechanisms of EPO 
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induced neuroprotection with the other animal models of stroke such as neonatal HI, 
global and focal ischemia and SAH. 
 
Erythropoietin-induced neuroprotection in adult cerebral ischemia 
EPO-induced neuroprotection in cerebral ischemia is associated with 
neurogenesis, angiogenesis, oligodendrogenesis, and improved cerebral blood flow and 
blood brain barrier integrity (Li et al., 2007; Chi et al., 2008; Zhang et al., 2010b).   
Sakanaka et al. demonstrated that intraventricular infusion of EPO in a gerbil model of 
forebrain ischemia decrease synapse degeneration and neuronal loss. The 
neuroprotective effects of EPO infusion was rapidly reversed by the addition of a soluble 
EPOR which enhance the ischemic core and total neuronal loss in the animals 
(Sakanaka et al, 1998).  EPO-induced neuroprotection in both transient and permanent 
MCAO appeared to be associated with increased pSTAT-5, Bcl-xL, (X-linked inhibitor of 
apoptosis protein) XIAP and decreased caspase 3 and 9 in neuronal tissue (Zhang et 
al., 2006; Fan et al., 2006). The upregulation of STAT-5 and the pan inhibition of 
caspase-3 and -9 appear to be conserved across the different stroke models.  
 
Erythropoietin-induced neuroprotection in Neonates 
Single or multiple doses of EPO administered pre- or post- HI was shown to 
promote neuroprotection in a rat model of neonatal hypoxia ischemia (Sun et al., 2004); 
(Kim et al., 2008). EPO-induced neuroprotection in neonatal rats is associated with 
reduced inflammation, apoptosis, brain atrophy, caspase 3 and 9 and increase 
expression of heat shock protein (HSP) 70 expression, JAK/STAT and TIMP-1 activity . 
Previous studies on the anti-inflammatory properties of EPO-induced neuroprotection in 
neonates showed that EPO inhibits/reduces cerebral expression of CD4+ and CD68+ 
cells interlukin (IL)-1 and tumor necrosis factor (TNF)  expression (Sun et al. 2005). In 
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addition to the anti-apoptotic and anti-inflammatory properties, EPO was also shown to 
stimulate progenitor cell proliferation in the dentate gyrus and subventricular zone of 
hypoxic ischemic (HI) neonates (Fan et al., 2011). These finding along with positive 
results in phase I/II clinical trial for EPO use in the treatment of neonatal hypoxic 
ischemic brain injury offer a glimmer of hope for EPO in stroke therapy (McPherson & 
Juul, 2010a) 
 
Clinical Use of Erythropoietin in Stroke Therapy 
Clinical trials in three different categories of stroke yielded divergent results. 
Single center study in China revealed that intravenous administration of 250 IU/kg of 
EPO thrice weekly for four weeks, significantly improved motor function in preterm 
infants at six months after birth (He et al., 2008). Subsequent studies were then 
conducted to determine the safety and efficacy of EPO used in neonates for the 
treatment of hypoxic ischemic brain injury (HIBI). Two independent single center studies 
revealed that high dose EPO improved neurodevelopment outcomes in very preterm 
infants and was safe and effective in doses ranging from 1000-2500IU/Kg (Fauchere et 
al., 2008; Juul et al., 2008). The dose was extrapolated to adults and yielded 
inconclusive or negative results (Tseng et al., 2010); Ehrenreich et al. 2009).  
Clinical analysis of the neuroprotective effects of EPO in SAH patients’ based on 
age, sepsis and concomitant Statin use revealed that the presence of sepsis attenuate 
EPO’s protection. Considering that sepsis is an attack on the hematopoietic system it is 
not surprising that it is difficult to harness its non-hematopoietic function of EPO in the 
presence of infection (Tseng et al., 2010). Harnessing the non-hematopoietic benefits of 
EPO in stroke therapy is a delicate balancing act. 
The past decade has shown a staggering number of failed clinical trials in stroke 
research. Many therapeutic interventions show promise in the laboratory but failed in the 
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clinics. Thus, a thorough understanding of mechanisms by which promising therapeutic 
intervention confers its neuroprotection is necessary to promote smoother transitions 
from bench to the bedside for EPO in stroke therapy 
Thus the central aim of this proposal is: to determine the key mediators of 
EPO-induced neuroprotection and the mechanisms by which this occurs in: in-
vitro and in-vivo models of hypoxia ischemia.  In support of this aim we formed the 
following hypothesis: exogenous administration of erythropoietin confers 
neuroprotection is dependent on its up-regulation of tissue inhibitor of matrix 
metalloproteinasee (TIMP)-1 and inhibition of hypoxia inducible factor (HIF)-1. 
This hypothesis is based on the following observations Firstly: Previous studies have 
confirmed that EPO triggers an increase in both mRNA and protein levels of TIMP-1 
(Kadri et al. 2000e). TIMP-1 forms a 1:1 complex with MMP-9 and inhibits its proteinase 
activities. Increased MMP-9 mediated apoptosis thus, its inhibition is associated with 
improved cell survival in both in vivo and in vitro model of hypoxia ischemia (Chen et al. 
2009?; Jiang et al. 2002;Baker et al. 2002). Secondly: HIF-1 target genes such as 
matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), 
cyclooxygenase (COX), nitric oxide synthase (NOS) and p53  plays a role in  vascular 
permeability, angiogenesis, inflammation and  cell death.  Previous studies have shown 
that inhibition of HIF-1 is neuroprotective (Chen 2008). Additionally preliminary findings 
in our lab indicate that EPO administration during hypoxia ischemia inhibits HIF-1 
protein expression in a dose dependent manner. Based on these observations, two aims 
are designed to test this hypothesis: 
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Specific Aims 
Specific Aim One 
Determine if tissue inhibitor of matrix metalloproteinase (TIMP)-1 mediates EPO-
induced neuroprotection in vivo and in vitro. Sub-aim 1A: is descriptive, it will 
demonstrate that EPO is neuroprotective in both models. The correlation between 
neuroprotection and increases in JAK-2/ STAT-3 and TIMP-1 activities and the 
subsequent down-regulation of MMP-9 will be shown. The optimum dose of EPO will be 
determined by cell death and infarction in vitro and in vivo respectively. JAK2 and STAT-
3 will be assessed by western blotting for the phosphorylated forms of the protein. MMP-
9 and TIMP-1 activity will be assessed by zymography and reverse zymography 
respectively. Sub-Aim 1B: is mechanistic: we will investigate if pharmacological inhibition 
of JAK-2 or TIMP-1 negates EPO induced neuroprotection during hypoxia ischemia in 
vitro and in vivo. Neuroprotection will be assessed by cell death and infarct volume in 
vitro and in vivo respectively. 
 
Specific Aim Two 
Determine the mechanism by which EPO regulates HIF -1 expression. Sub-aim: 
2A is descriptive: We will profile the expression of HIF-1 and HIF -2 in response to 
EPO treatment during OGD. HIF-1 and HIF-2 has 40% homology. HIF-2 has been 
shown to bind to the beta subunit of HIF1 during hypoxia (Krieg et al., 2000b). Thus it is 
necessary to profile both isoforms to determine if EPO is inhibiting both. Cell survival 
during oxygen and glucose deprivation will be used to determine the optimum dose of 
EPO. HIF-1 and HIF-2 protein expression and activity will be determined by western 
blotting and reverse transcriptase polymerase chain reaction (RT-PCR) respectively. It is 
hypothesized that both HIF-1 and not HIF-2 will decrease with EPO treatment.  
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Sub-aim 2B: is mechanistic and will determine the profile of HIF-1 alpha regulators ROS, 
PHD-2 and VHL in EPO treatment of OGD cells. Two techniques dichlorofluorescein and 
myeloperoxidase assay will be used to assess ROS production. Both PHD-2 and VHL 
expression will be assessed by western blotting and RT-PCR. It is expected that there 
will be an increase in PHD and VHL expression and a decrease in the generation ROS 
in the EPO treated cells. Sub-aim 3C: Will verify the mechanism of EPO’s inhibition of 
HIF-1α using pharmacological manipulations of EPOR and PHD2. EPOR receptor 
antagonist EMP9 will be used to block the binding of EPO during OGD in EPO treated 
cells. PHD2 inhibitor FG4095 will be used to inhibit PHD 2 expression in OGD cells. HIF-
1  and PHD-2 expression and activity and the generation of ROS in all groups will be 
compared to control. It is expected that both EPOR antagonist and PHD-2 will negate 
the neuroprotective effects of EPO as well as its inhibition of HIF-1. 
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Figure 1.1. Schematic representation of the overall research proposal: the central 
hypothesis and aims being studied 
Aim 1 illustrated in green proposes that binding of exogenous rhEPO to its receptor 
stimulates the phosphorylation of Janice Kinase 2 which in turn phosphorylates STAT-3. 
The phosphorylated STAT-3 is then translocated to the nucleus where it initiates TIMP-1 
transcription. The increase in TIMP-1 inhibits MMP-9 thereby promoting cell survival. 
Aim 2 illustrated in orange shows the pathophysiological response to hypoxia ischemia 
or oxygen and glucose deprivation. This aim proposes that treatment with exogenous 
rhEPO inhibits HIF-1a. The possibility of direct or indirect inhibition via ROS or PHD-2 
will be examined.   
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Abstract 
Previous studies have shown that erythropoietin (EPO) is neuroprotective in both 
in vivo and in vitro models of hypoxia ischemia. However theses studies hold limited 
clinical translations because the underlying mechanism remains unclear and the key 
molecules involved in EPO-induced neuroprotection are still to be determined. This 
study investigated if tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and if its 
upstream regulator signaling molecule Janus kinase-2 (JAK-2) are critical in EPO-
induced neuroprotection. Hypoxia Ischemia (HI) was modeled in-vitro by oxygen and 
glucose deprivation (OGD) and in-vivo by a modified version of Rice-Vannucci model of 
HI in 10-day-old rat pups.  
EPO treated cells were exposed to AG490, an inhibitor of JAK-2 or TIMP-1 
neutralizing antibody for 2 hours with OGD. Cell death, phosphorylation of JAK-2 and 
signal transducers and activators of transcription protein (STAT)-3, TIMP-1 expression, 
and matrix metalloproteinase-9 (MMP-9) activity were measured and compared with 
normoxic group. Hypoxic ischemic animals were treated one hour following HI and 
evaluated 48 hours after. Our data showed that EPO significantly increased cell survival, 
associated with increased TIMP-1 activity, phosphorylation of JAK-2, STAT-3, and 
decreased MMP-9 activity in vivo and in vitro. EPO’s protective effects were reversed by 
inhibition of JAK-2 or TIMP-1 in both models. We concluded that JAK-2, STAT-3 and 
TIMP-1 are key mediators of EPO-induced neuroprotection during hypoxia ischemia 
injury.  
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TIMP: Tissue Inhibitor of matrix Metalloproteinase 
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Introduction 
Asphyxia is the disruption of placental/ pulmonary gas exchange. It is associated 
with hypoxemia, respiratory and systemic acidosis, which are linked to cerebral hypoxia 
ischemia in neonates (Vannucci 2000). Erythropoietin (EPO), a hematopoietic growth 
factor, with non-hematopoietic functions, is upregulated during hypoxia ischemia in the 
brain of most mammals (Prass et al. 2003). Although the upregulation of endogenous 
EPO is not enough to confer neuroprotection during hypoxia, it is able to turn on some of 
the necessary pro-survival pathways (Shein et al. 2008). Previous studies have shown 
that exogenous administration of EPO confers neuroprotection in both in vitro and in vivo 
models of cerebral ischemia (Brines et al. 2000; Sakanaka et al. 1998; Sun et al. 2005). 
Our understanding of the mechanism by which this occurs is still unfolding. 
Physiologically, EPO binds to the EPO receptor (EPOR) and promotes cellular 
differentiation, proliferation and inhibition of apoptosis (Brines et al. 2000; Sakanaka et 
al. 1998; Sun et al. 2005). It also prevents damage against mechanical trauma, 
excitotoxins, and neuro-inflammation (Brines et al. 2000; Sakanaka et al. 1998; Sun et 
al. 2005).  
Previous studies have shown that EPO and other hematopoietic growth factors 
are associated with the Janus Kinase (JAK)-2 tyrosine kinases (Harpur et al. 1992; 
Witthuhn et al. 1993). Janus Kinases are a family of receptor tyrosine kinases 
associated with membrane receptors and are phosphorylated when specific ligands bind 
to its receptor. JAK-2 kinases phosphorylate cytosolic transcription factors, signal 
transducers and activators of transcription (STAT), allowing for the transcription of 
proteins such as: cytokines, growth factors, cell survival and differentiation factors 
depending on the ligand (Ihle 1995b; Ihle 1995a; Shuai et al. 1992; Kaplan et al. 1996). 
STAT-3 and STAT-5 are both associated with the EPOR and are both activated by the 
binding of EPO to its receptor (Ruscher et al. 2002; Toth et al. 2008). STAT-3, the more 
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primordial STAT is highly associated with embryonic development. It is the less studied 
of the EPOR activated STATs, and is shown to bind to the promoter sequence of the 
tissue inhibitor of matrix metalloproteinase (TIMP) -1 gene (Bugno et al. 1995, 
Dominguez et al. 2008). TIMP-1 is associated with erythroid cell survival, growth and 
differentiation in the presence of EPO (Kadri et al. 2000; Bugno et al. 1995).  
TIMPs are a family of four secreted proteins (TIMPs 1-4) that function in 
maintaining extracellular matrix homeostasis (Gomez et al. 1997; Carmichael et al. 
1986; Stetler-Stevenson 1990; Stetler-Stevenson et al. 1990). TIMPs are endogenous 
inhibitors of matrix metalloproteinases (MMP), a family of protein-degrading zinc 
dependant endopeptidases (Jiang et al. 2002; Baker et al. 2002). The delicate balance 
between TIMPs and MMPs regulates extracellular matrix, receptor shedding and growth 
factor bioavailability (Sternlicht & Werb, 2001). MMPs are important in embryonic 
development, angiogenesis, wound healing, inflammation, cancer, and tissue 
destruction. MMPs cleave most of the extracellular matrix (ECM) and are involved in the 
breakdown and remodeling of many tissues and organs (Birkedal-Hansen et al., 1993; 
Isaksen and Fagerhol, 2001). Because of its ability to degrade ECM, changes in the 
MMP-9 to TIMP-1 ratio leads to excessive tissue degradation and cell death. The 
delicate balance is usually altered during hypoxia leading to a significant increase in 
MMPs secretion that is not proportional to that of TIMPs (Reynolds, 1996; Ejeil et al., 
2003; Andrian et al., 2007). Previous studies have confirmed that EPO triggers an 
increase in both mRNA and protein levels of TIMP-1 (Kadri et al. 2000). TIMP-1 forms a 
1:1 complex with MMP-9 and inhibits its proteinase activities. Increased MMP-9 
mediated apoptosis thus, its inhibition is associated with improved cell survival in both in 
vivo and in vitro model of hypoxia ischemia (Chen et al. 2008; Jiang et al. 2002; Baker et 
al. 2002). Additionally, an inverse correlation with MMP-9 expression and activity and 
erythroid cell survival has been shown (Kadri et al. 2000). However, this correlation was 
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not shown in non-hematopoietic cells such as neurons and the relevance of TIMP-1 in 
EPO induced neuroprotection in vivo and in vitro is still to be elucidated.  
In this study, we sought to determine whether TIMP-1 expression and anti-
gelatinase activity are important in EPO induced neuroprotection during hypoxia 
ischemia. Cerebral hypoxia ischemia was modeled in vitro by oxygen and glucose 
deprivation (OGD) in PC12 cells and in vivo by permanent ligation of the right common 
carotid artery followed by two hours of hypoxia in 10-day-old (P-10) rat pups (Zagorska 
and Dulak 2004; Vannucci et al. 1999). We examined the expression of TIMP-1, 
phosphorylated JAK-2 and STAT-3, as well as the activities of TIMP-1 and MMP-9 with 
EPO treatment during OGD. We then investigated if pharmacological inhibition of JAK-2 
or TIMP-1 negated EPO induced neuroprotection during hypoxia ischemia in vitro and in 
vivo. The endpoints used to determine neuroprotection were cell death and infarct 
volume in vitro and in vivo respectively.  
 
Materials and Methods 
Materials 
Rat pheochromocytoma (PC-12) cells, fetal bovine serum (FBS) and horse 
serum (HS) were obtained from ATCC (Manassas, VA). Procrit ©, human recombinant 
erythropoietin was from Loma Linda University, Hospital Pharmacy (Loma Linda, CA.). 
Neuronal growth factor (NGF) was from Alomone Laboratories Ltd. (Jerusalem, Israel). 
Reverse zymography kit was from University of East Anglia, School of Biological 
Sciences (Norwich UK). TIMP-1 neutralizing antibody was from AbD Serotec (Raleigh, 
NC). AG490 was from Calibiochem (San Diego, CA). Rabbit phospho-STAT-3 (Tyr705) 
(D3A7) monoclonal antibody was from Cell Signaling (Danvers MA). Rabbit phospho-
JAK-2 (Tyr1007/1008) polyclonal antibody, rabbit anti- JAK-2 and mouse TIMP-1, clone 
7-6C1 monoclonal antibody was obtained from Millipore Biosciences (Temecula, CA). 
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Rabbit anti STAT-3, β−actin and all secondary antibodies were from Santa Cruz 
Biotechnology. Cell death ELISA was from Roche Diagnostics (Indianapolis, IN). All 
other reagents were obtained from Fisher Scientific (Tustin, CA).  
 
Methods 
Culturing and Differentiation of Cells 
PC-12 cells passage 6 through 9 were used. Cells were grown on 100 mm2 poly-
D-lysine plates in Dulbeco's modified Eagle's medium (DMEM) supplemented with: 5% 
FBS, 10% HS, 1% Penicillin/streptomycin , 25 mM glucose, 50 ng/ml NGF and 
incubated at 37°C in 5% CO2 for 7 days as previously described (Greene 1976;Dickson 
et al. 1986). . 
 
Treatment of Cells 
Normal media was replaced with glucose-free, supplemented DMEM with either 
0,3,10 or 30 U/ml EPO. Cells were placed in a hypoxic chamber with less than 1% 
oxygen for 2 hours (Agani et al. 2002). Treatment media was discarded and cells were 
allowed to recover for 18 hours under normal conditions and collected for zymography, 
reverse zymography, western blotting, trypan blue exclusion and cell death ELISA. Cells 
were treated with 25 mM of AG490 during OGD for the inhibition of JAK/STAT and 3 
μg/mL of TIMP-1 neutralizing antibody for inhibition of TIMP-1.  
 
Protein extraction from PC-12 cells  
Protein was extracted as previously described (Andrews and Faller 1991). 
Briefly, cells were detached by scraping, rinsed with cold PBS, centrifuged and 
supernatant discarded. Two hundred  μL of radio-immuno-precipitation assay (RIPA) 
lysis buffer [20 mM Tris, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% Na deoxycholate, 1 mM 
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EDTA, and 0.1% sodium dodecyl sulfate (SDS)] supplemented with protease and 
phosphatase inhibitor cocktails (Sigma-Aldrich, St. Louis, MO) were added and the 
suspension shaken for 15 minutes at 4°C followed by centrifugation. Protein 
concentrations were estimated by Bradford Assay (BioRad, Hercules, CA). Samples not 
used immediately were aliquoted stored at -80°C for later use. 
 
Cell Death Assay 
Cell death was assessed by trypan blue exclusion and cell death ELISA 
according to manufacturer’s protocol (Roche Diagnostics, Indianapolis, IN.) Briefly, cells 
were collected by scraping. Sixteen μl of cell suspension mixed with 4 μl of trypan blue 
and allowed to sit for 5 minutes. Cells were re-suspended and counted on a 
hemocytometer thrice by two independent investigators. The formula used to calculate 
percent cell death was as follows: (Trypan blue positive cells)]/ total cell counted) x 100. 
The average of all six counts was used. There was an n of six per group.  
 
Western Blotting  
Western blotting was done as previously described (Dominguez et al. 2008). A 
30μg sample of total protein per well with Laemmli sample buffer (62.5 mM Tris-HCl, pH 
6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue and 5% β-mercaptoethanol) was 
denatured at 90°C for 3-5 minutes prior to loading on a 4-12% Bis Tris gel (Biorad, 
Hercules, CA). Gel was electrophoresed and protein transferred to nitrocellulose 
membrane. The membrane was blocked with nonfat blocking grade milk (Biorad, 
Hercules, CA) and probed with the appropriate dilutions of primary and secondary 
antibodies to either JAK-2, pJAK-2, STAT-3, pSTAT-3, TIMP-1 or β−actin. Membranes 
were washed and protein visualized using ECL Plus, Chemiluminescence (GE 
Healthcare and Life Sciences, Piscataway, NJ). The optical densities of the bands were 
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calculated with Image J, version 1.0 and normalized to β-actin which was used as a 
loading control for all proteins studied. 
 
Gelatin Zymography  
Gelatin zymography was performed as previously described (Tang et al. 2004; 
Wang et al. 2000; Wu et al. 2010). Briefly, 60 μg samples of protein extract were 
prepared and separated by electrophoresis in 10% Tris-glycine gel with 0.1% gelatin as 
substrate (Bio-Rad, Hercules, CA). The gel was re-natured for one hour and then 
incubated with development buffer at 37°C for 48 hours. After development, the gel was 
stained with 0.5% coomassie brilliant blue R-250 for one hour and then destained 
appropriately. MMP activity was quantified. Optical densities were calculated with Image 
J (version 1.0) software. 
 
Reverse Zymography  
Reverse zymography was performed according to manufacturer’s protocol. 
Briefly, 60μg samples cell lysate (total protein) was mixed with (1:2 ratio) zymography 
sample buffer [62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 4% SDS, 0.01% Bromophenol 
Blue] (Bio-Rad, Hercules, CA), and loaded on a 15% gelatinase gel. Electrophoresis was 
performed at 140V, and then gels were rinsed and incubated at 37oC for 48hours. 
Stained withTIMP-1 and TIMP-2 were observed as dark bands as indicated by TIMPs 
standard (East Anglia University, Norwich UK). TIMP-1 activity was quantified, and 
optical densities were calculated with Image J, version 1.0. 
 
Neonatal Hypoxic Ischemic Model  
All animal research was conducted in accordance with protocols approved by 
Loma Linda University Institutional Animal Care and Use Committee (IACUC). Time 
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pregnant female Sprague-Dawley rats (n=5) (Harlan Laboratories, Indianapolis, IN) with 
their dams were housed in light and temperature controlled environment with food and 
water ad libitum for the duration of the study. Hypoxia ischemia (HI) was performed as 
previously described (Calvert et al. 2002). Briefly, the right common carotid artery of 
anesthetized (2.5% isoflourane in 30% O2 and 70% medical air) post-natal day 10 pups 
(n=56) were permanently ligated, followed by one hour of rest and 2.5 hours of hypoxia 
(8% O2 balance N2). The pups were returned to their respective dams and maintained at 
ambient temperature for 24 hours. Animals were sacrificed under deep anesthesia at 48 
hours post hypoxia and samples collected for 2, 3, 5-triphenyltetrazolium chloride 
monohydrate (TTC) staining, imunohistochemistry, western blotting, zymography or 
reverse zymography.  
 
Intracerebral Ventricular Injection 
Intracerebral ventricular injection was performed 1 hour prior to HI, as previously 
described by Pang et al. (Pang et al. 2003). All drugs were concentrated so that animals 
received no more than 0.5 μl of fluid in the ventricle. Dose response curves for both 
TIMP-1 neutralizing antibody and AG490 were performed to determine the optimum 
doses. The doses presented in this study were 300 ng per pup of TIMP-1 neutralizing 
antibody and 15 μM of AG490. The vehicles used were IgG and 10% DMSO 
respectively. Sham operated animals were given a needle stick using the same 
coordinates as vehicle and treated animals to minimize/eliminated difference due to 
surgical techniques.  
 
Infarct Volume  
Infarct volume was assessed by TTC staining as previously described (Yin et al. 
2003). Briefly, pups were euthanized by isoflurane inhalation. Brain was immediately 
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removed and sectioned into 2 μm slices. The slices were submerged in 2% TTC solution 
for 5 minutes at 37°C and rinsed with cold phosphate buffered saline (PBS). Sections 
were then fixed with 10% formaldehyde. The slices were photographed and analyzed 
using Image J, version 1.0 software by different researchers both of whom were blinded 
to the groups in this study. The following formula was used to calculated percent infarct 
[(total area of contralateral hemisphere X 2) – (area of uninfarcted area of ipsilateral 
hemisphere)]/ (total area of contralateral hemisphere X 2) for each slice. 
 
Immunohistochemistry  
Transcardial perfusion was performed as previously described (Hu et al. 1999; 
Leonardo et al. 2010). Briefly, following anesthesia with 3.0% isoflurane for 3 to 5 
minutes, pups were thoracotomized. A catheter was placed in the apex of the left 
ventricle and an incision was made on the right atrium. The pups were perfused with 40 
ml of PBS followed by 40 ml of 10% formalin. Collected brain tissues were first fixed in 
10% formalin and then cryopreserved in 30% sucrose solution. The tissues were frozen 
in optimal temperature cutting (OTC) solution (Fisher Scientific, Tustin CA) and 
sectioned into 10 μm coronal slices by cryostat (CM3050S, Leica Microsystems, 
Bannockburn, IL). The 10 μm sections were incubated with primary mouse anti- TIMP-1, 
rabbit anti-MMP-9 (Millipore) or goat anti-MAP-2 (Santa Cruz Inc.) overnight at 4°C. 
Fluorescence dye-conjugated secondary antibodies (Jackson Immuno Research, West 
Grove, PA) fluorescein isothiocyanate (FITC; green fluorescence) donkey anti-mouse, 
Texas red-conjugated donkey anti-rabbit IgG and AMCA-conjugated affinity pure donkey 
anti-goat (Blue) were used. Sections were then observed under an Olympus B 51 
microscope with a digital camera and Image-Pro plus software. 
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Statistical Analysis  
Data are presented as mean ± standard deviation. All data were validated using 
one way ANOVA followed by Tukey or Dunn’s test. Statistical evaluation was performed 
using Sigma Stat software version 3.5 (DUNDAS software LTD. Germany). 
 
Results 
Determining the Optimum Dose of Erythropoietin in vitro 
To investigate the most effective dose of EPO during OGD, cells were treated 
with 0,3,10 or 30 U/ml of EPO. After 18 hours of recovery, cell death was determined 
quantitatively by trypan blue exclusion (figure 2.1.A, n=6) and qualitatively by ELISA 
(figure 2.1.B, n=5). As compared with untreated, medium dose EPO 10 U/ml conferred 
the most protection. Both low (3 U/ml) and high (30 U/ml) doses were ineffective in 
minimizing cell death during OGD. Medium dose (10 U/mL) conferred significant 
neuroprotection (p< 0.05) compared to the untreated group making this the most 
effective dose (Figure 2.1.). 
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Figure 2.1. The Optimum dose of Erythropoietin for neuroprotection during 
Oxygen and Glucose Deprivation in vitro. (A) Cell viability as assessed by trypan blue 
exclusion following HI and 18hrs of recovery. Data represent the mean (±SD): n = 6 in all 
groups. (B) Cell viability as determined by cell death ELISA. Data represent the mean 
(±SD): n = 5 in all groups. *P < 0.05 compared to untreated. # P< 0.05 compared to 
10U/ml EPO group. 10U/mL conferred the most neuroprotection. 
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Phosphorylation of JAK-2 and STAT-3 in vitro  
To examine if phosphorylation of JAK-2 and STAT-3 are involved in EPO 
induced neuroprotection we profile the expression of the phospho-proteins in the 
presence and absence of their inhibitors and EPO during OGD in NGF differentiated PC-
12 cells. Figure 2:2 B shows a significant increase in JAK-2 phosphorylation (p<0.05) in 
EPO treated group compared to normoxic, untreated and JAK inhibitor group (25 μM 
AG490). The expression of phosphorylated STAT-3 was also significantly increased in 
the 10U/mL EPO treated group (p<0.05) compared to that of all other groups Figure 
2.2.C. This indicates EPO has an effect on both JAK-2 and STAT-3 phosphorylation 
when used to treat NGF differentiated PC-12 cell during OGD. 
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Figure 2.2. The profile of pJAK-2 and pSTAT-3 after the inhibition JAK-2 and TIMP-
1 during 2 hours of OGD. (A) Shows representative blots of pJAK-2, pSTAT-3 and the 
b-actin used as the loading control. (B) JAK-2 phosphorylation in the presence of JAK-2 
and TIMP-1 inhibitors.(c) STAT-3 phosphorylation in the presence of JAK-2 and TIMP-1 
inhibitors. Data represent the mean (±SD): n = 5 in all groups. .* P< 0.05 compared to 
untreated # P< 0.05 compared to the 10U/ml EPO treated group. Phosphorylation of 
both JAK-2 and STAT-3 was increased with EPO treatment and reversed by inhibitors. 
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TIMP-1 Expression and TIMP-1 and MMP-9 activity Following OGD in 
Cultures 
To determine the importance of TIMP-1 expression in EPO induced 
neuroprotection, we profiled the expression and activity of TIMP-1 and its substrate 
MMP-9 in the presence and absence of TIMP-1 inhibition and EPO during OGD. A 
neutralizing antibody was used to inhibit TIMP-1 (3 μg/ml). Thus, it was not surprising 
that although there was a visible increase in TIMP-1 expression figure 2.3.A row 1 
representative blot and figure 2.3(b) densiometric quantification.  It was expected that 
only the biological activity and not the expression of TIMP-1 would be altered by the use 
of a neutralizing antibody, which was shown in figure 2.3.A row 3 representative gel and 
figure 2.3.C densiometric quantification .TIMP-1 activity was significantly increased in 
EPO treated group (p<0.05) compared to the other groups. There was an inverse 
correlation between TIMP-1 and MMP-9 activity figure 2.3.A representative gel and 
figure 2.3.D densiometric quantification. MMP-9 activity was significantly decreased 
(p<0.05) in the presence of EPO treatment compared to untreated. 
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Figure 2.3. The Expression of TIMP-1 and Activity of TIMP-1 and MMP-9 in the 
presence of JAK-2 and TIMP-1 inhibitors 18 hours after OGD.  (A) Representative 
blot (WB) of TIMP-1 and b-actin expression and coomassie blue stain of TIMP-1 activity 
(dark bands) and MMP – activity (light bands), column 0 shows positive controls for 
TIMP-1 and MMP-9. (B) Densitometric quantification of western blot for TIMP-1 
expression. (C) Densiometric calculation of reverse zymography of TIMP-1 activity. (D) 
Densiometric quantification of zymography of MMP-9 activity.  Data represent the mean 
(±SD): n = 6 in all groups represented in B,C and D. * P < 0.05 in all group compared to 
untreated. # P < 0.05 compared to 10U/mL EPO treated group. EPO treatment 
increased TIMP-1 activity and expression and reduced MMP-9 activity.  
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Reversing EPO’s Neuroprotection  
TIMP-1 or JAK-2 inhibitors were added to OGD cells in the presence or absence 
of EPO to determine if these molecules were necessary for EPO-induced 
neuroprotection. Neuroprotection was assessed by cell death assays. Inhibition of either 
JAK-2 or TIMP-1 negated the neuroprotective effects of EPO Figure 2.4. Both trypan 
blue exclusion Figure 2.4.A and cell death ELISA Figure 2.4.B showed a significant 
increase in cell survival in the presence of EPO treatment compared to untreated and 
inhibitor groups. EPO induced cell survival was attenuated in the presence of both 
inhibitors.  
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Figure 2.4. The effect of 2 hours of inhibition of JAK-2 and TIMP-1 during OGD on 
cell death. Cell death assays showing the neuroprotective effects of EPO is reduced in 
the presence of JAK-2 and STAT-3 inhibitors during OGD. Cell viability as assessed by: 
(A) trypan blue exclusion (n=6) and (b) cell death ELISA (n=5) following HI and 18hrs of 
recovery. Data represent the mean (±SD). * P< 0.05 compared to untreated. #P < 0.05 
in all group compared to 10U/EPO treated group. 
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Phosphorylated JAK-2, Phosphorylated STAT-3 is Necessary for 
Protection in vivo 
To determine if the role of JAK-2 and STAT-3 in EPO-induced neuroprotection is 
similar in animal to that observed in cultures, we profile the phosphorylation of JAK-2 
and STAT-3 in the presence and absence of their inhibitors and EPO in the ipsilateral 
cortex of neonatal hypoxic ischemic pups. Figure 2.5.C shows a significant increase in 
JAK-2 phosphorylation (p<0.05) in sham, IgG +EPO and DMSO +EPO compared to IgG 
vehicle and DMSO vehicle as well as TIMP-1 inhibitor with and without EPO. The 
expression of phosphorylated STAT-3 was also significantly increased in the IgG+ EPO 
and DMSO + EPO groups (p<0.05) compared to TIMP-1 inhibitor groups with and 
without EPO and JAK-2 inhibitor groups with and without EPO, Figure 2.5.C. This 
suggests a role for JAK-2 and STAT-3 in EPO-induced neuroprotection in vivo. 
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Figure 2.5. The profile of phosphorylated JAK-2 and phosphorylated STAT-3 in the 
ipsilateral cortex of the brain of HI rats  (48 hrs) after inhibition of JAK2 or TIMP-1  
(A) Shows a representative blots of pJAK-2, pSTAT-3 and the b-actin used as the 
loading control. (B) JAK-2 phosphorylation in the presence of JAK-2 and TIMP-1 
inhibitors. (C) STAT-3 phosphorylation in the presence of JAK-2 and TIMP-1 inhibitors. 
Data represent the mean (±SD): n = 6 in all groups. .* P< 0.05 compared to untreated. # 
P< 0.05 compared to the 10U/ml EPO treated group. EPO treatment increase the 
phosphorylation of JAK-2 and STAT-3 and the inhibitors decreased both. 
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TIMP-1 Expression and TIMP-1 and MMP-9 Activity in vivo 48 hours 
after Hypoxia Ischemia 
To determine the importance of TIMP-1 expression in EPO induced 
neuroprotection, we profiled the expression and activity of TIMP-1, and its substrate, 
MMP-9 in the presence and absence of TIMP-1 inhibition and EPO during HI. A 
neutralizing antibody was used to inhibit TIMP-1 (300ng/pup). Neutralizing antibodies 
binds to the active site of the protein thereby physically inhibiting the interaction of that 
protein with its substrate.  Thus, it was not surprising that although there was a visible 
increase in TIMP-1 expression figure 2.6.A row 1 representative blot and figure 2.6.B 
densiometric quantification there was no significant difference between the TIMP-1 
inhibitors group and the IgG + EPO groups. .  It was expected that only the biological 
activity and not the expression of TIMP-1 would be altered by the use of a neutralizing 
antibody, which was shown in figure 2.6.A row 3 representative gel and figure 2.6.A 
densiometric quantification .TIMP-1 activity was significantly increased in  the IgG +EPO 
group (p<0.05) compared to the other groups. There was an inverse correlation between 
TIMP-1 and MMP-9 activity figure 2.6.A row 4 representative gels and figure 2.6.D 
densiometric quantification. MMP-9 activity was significantly decreased in the IgG +EPO 
group (p<0.05) compared to IgG vehicle, EPO+ TIMP-1 inhibitor and EPO + JAK-2 
inhibitor. Suggesting that both JAK-2 and TIMP-1 are involved in EPO induce 
neuroprotection in vivo. 
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Figure 2.6. The Expression of TIMP-1 and Activity of TIMP-1 and MMP-9 in the 
presence of JAK-2 and TIMP-1 inhibitors 48 hours after HI in the brain.  (A) 
Representative blot (WB) of TIMP-1 and b-actin expression and coomassie blue stain of 
TIMP-1 activity (dark bands) and MMP –9 activity (light bands), column 0 shows positive 
controls for TIMP-1 and MMP-9. (B) Densitometric quantification of western blot for 
TIMP-1 expression. (C) Densiometric calculation of reverse zymography of TIMP-1 
activity. (D) Densiometric quantification of zymography of MMP-9 activity.  Data 
represent the mean (±SD): n = 6 in all groups represented in B, C and D. * P < 0.05 in all 
group compared to IgG vehicle # P < 0.05 compared to IgG + EPO group. EPO 
treatment increased TIMP-1 activity and expression and reduced MMP-9 activity. 
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Co-localization of TIMP-1 and MMP-9, 48 hours after hypoxia 
ischemia in vivo 
To determine that the increase in TIMP-1 expression seen with EPO treatment in 
vitro also occurred in vivo, we performed immunohistochemistry staining for TIMP-1 and 
MMP-9 in HI animals with EPO using JAK-2 or TIMP-1 inhibitor (Figure 2.7). There was 
an increase in TIMP-1 expression and a corresponding decrease in MMP-9 expression 
in the cortex and hippocampus of animals and visible co-localization between TIMP-1 
and MMP-9 in neurons indicating that there is interaction between the two. The optimum 
dose of both JAK-2 inhibitor (AG490) and TIMP-1 neutralizing antibody was determined 
by dose response curves (data not shown). The dose that reduced JAK-2 expression 
and TIMP-1 activity without exacerbating injury was used. The optimum dose of AG490 
used in vivo was 15 μM/pup. The dose of TIMP-1 neutralizing antibody used was 300 
ng/pup. There was no visible difference between the inhibitor only groups and the 
inhibitor with EPO groups so only the inhibitors plus EPO group were shown in the figure 
2.7.  
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Figure 2.7. TIMP-1 and MMP-9 expression in the brain of neonatal hypoxic 
ischemic rats after inhibition of JAK-2 and TIMP-1. The expression of TIMP-1 (Texas 
Red) and MMP-9 (green, FITC) in neurons (blue, AMCA) in the hippocampus (A, left 
panel) and cortex (B, right panel) of neonatal HI animals treated with (5U/g) EPO. Merge 
of TIMP-1 and MMP-9 with and without EPO are shown in the right panes. The co-
localization of TIMP-1 and MMP-9 in neurons 48 hours after hypoxia ischemia in EPO 
treated neonatal rats. Both inhibitors suppressed the upregulation of TIMP-1 in the 
presence of EPO treatment. 
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Inhibition of JAK-2 or TIMP-1 reverses EPO’s neuroprotection in vivo  
EPO was effective in conferring neuroprotection in 10 day old neonatal hypoxic 
ischemic pups. Similar to the in vitro results of EPO’s neuroprotective effects were 
reversed by inhibition of either JAK-2 or TIMP-1 in vivo resulting in increased tissue 
infarction figure 2.8.A representative brain slices, figure (2.8.A quantification of infarction. 
Tissue infarction/cell death was significantly decreased in EPO treated animals without 
inhibitor compared to both vehicle and inhibitor treated animals. 
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Figure 2.8. Triphenyltetrazolium chloride (TTC) staining of brain tissue of neonatal 
hypoxic ischemic pups after inhibition of JAK-2 and TIMP-1 (a) Representative 
cross-sections from the brain of ischemic rat pups are depicted from anterior top) to 
posterior (bottom). The white areas show the area of infarction for that pup at that 
particular cross-sectional level. The mean (±SD) percent area of infarction is 
represented on the graph in (b). (n=6 for sham) (n= 8 for all other groups). * P < 0.05 in 
all group compared to IgG vehicle: #P < 0.05 in all group compared to 10U/EPO treated 
group. Inhibition of JAK or TIMP-1 reverses EPO’s protection in vivo.   
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Discussion 
Our findings showed that the upregulation of TIMP-1 by exogenous EPO is 
necessary for EPO-induced neuroprotection following neonatal hypoxia ischemia or 
oxygen and glucose deprivation. We also found that EPO-induced neuroprotection was 
associated with increased phosphorylation of the JAK-2 receptor, downstream signal 
transducer STAT-3 and its transcription product TIMP-1 and significantly lower MMP-9 
activity. 
 Erythropoietin is up-regulated during ischemia in the brain of most mammals 
(Prass et al., 2003). EPO released in response to low oxygen promotes cellular 
differentiation, proliferation and inhibition of apoptosis (Brines et al. 2000; Sakanaka et 
al. 1998; Yoshimura 1998). Previous studies have shown that exogenous administration 
of EPO is associated with neuroprotection in vivo and in vitro which was corroborate by 
our findings (Sun et al. 2005; Ruscher et al 2002).  The optimum dose of EPO needed to 
produce these effects varies from cell type to cell type (Ruscher et al. 2002; Kadri et al. 
2000; Renzi et al. 2002). Chan et al. showed that the optimum dose for JAK-2 activation 
and MMP-9 inhibition and subsequent protection of cultured ischemic hearts was 5 U/mL 
(Chan et al 2007). Interestingly EPO was shown to confer neuroprotection at a 
significantly lower dose of 0.1 U/mL (Rusher et al. 2002).   Our results showed that 10 
U/mL of EPO were the optimum dose for neuroprotection in NGF differentiated PC-12 
cells. We demonstrated the mechanism by which this occurred and the importance of 
TIMP-1 activity in this protection. Several studies have shown that EPO is associated 
with the family of JAK receptor tyrosine kinases. It is believed that binding of EPO to its 
receptor EPOR promotes the phosphorylation of JAK-2 (Lacombe and Mayeux 1999a; 
Lacombe and Mayeux 1999b; Constantinescu et al. 1999). The phosphorylated receptor 
recruits different signaling molecules such as STAT proteins 1-6 for phosphorylation, 
depending on the specific ligand bound to the receptor (Ihle 1995b; Ihle 1995a; Shuai et 
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al. 1992; Kaplan et al. 1996b). The phosphorylated STAT is translocated to the nucleus 
where it binds to the promoter of specific genes and initiates transcription of that gene 
(Ihle 1995b; Ihle 1995a; Shuai et al. 1992; Kaplan et al. 1996b). The specific STAT that 
is associated with EPO is still controversial. According to Chen et al STAT-5, one of the 
most widely studies transcription factors, is associated with EPOR binding. STAT-5 
promotes the transcription of anti-apoptotic gene BCL-XL and activation of Ras mitogen 
activated protein kinase (MAPK), ERK-1/-2, and PI3K/Akt pathways (Chen et al. 2003; 
Kilic et al. 2005). However, contrary to previous suggestion that STAT-3 is not involved 
in EPO’s signaling; our results show that phosphorylated STAT-3 is involved in EPO 
induced neuroprotection (Rusher et al 2002). This contradiction could possibly be 
explained by the passage of cells and the age of the animals studied. In our studies we 
used neonatal models of hypoxia ischemia. Neonatal animals are more likely to express 
higher levels of STAT-3 than their adult counterparts because STAT-3 is a primordial 
STAT associated with embryonic development (Murphya et al 2005.). Additionally, 
STAT-3 is shown to be induced in response to injury in peripheral nerves. It is also 
shown to be involved in axonal regeneration (Schwaiger et al. 2000; Sheu et al. 2000; 
Qiu et al. 2005). Studies have shown that STAT-3 binds to the promoter sequences of 
TIMP-1, which is associated with erythroid cell survival, growth and differentiation in the 
presence of EPO (Kadri et al. 2000b; Bugno et al. 1995). Our study demonstrates that in 
non-erythroid cells, EPO up-regulates TIMP-1 by phosphorylation of its transcription 
factor STAT-3. Concordantly, there was a significant decrease in cell viability of EPO 
treated cells if the JAK/STAT pathway was inhibited or there was a lower expression of 
phosphorylated STAT-3. We did not study STAT-5 as the role of STAT-5 in EPO 
induced neuroprotection was previously shown.  We did not detect an induction of MMP-
2 during OGD in vitro and we observed that MMP-2 was constituently expressed in vivo 
48 hours after HI thus we only focused on MMP-9. 
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In this present study EPO treatment was accompanied by increased 
phosphorylation of JAK-2, STAT-3 and TIMP-1 expression and activity. Kadri et al. 
showed EPO induced increase in TIMP-1 expression in erythroid cells (Kadri et al. 
2000b; Bugno et al. 1995). However, since EPO is shown to have different effects in non 
hematopoietic cells, we needed to verify if TIMP-1 is important for EPO induced 
neuroprotection. Our findings showed that TIMP-1 neutralizing antibody (figure 2.3.A and 
2.3.B) did not significantly alter TIMP-1 expression which was not surprising. 
Neutralizing antibody alters/inhibits the biological function/activities of 
cells/receptors/proteins but does not change the protein levels. We observed an inverse 
correlation between TIMP-1 and MMP-9 activity in the presence of EPO. This finding is 
consistent with studies done by earlier authors which show similar correlations in 
erythroid cells (Kadri et al. 2000b; Bugno et al. 1995). Our in vivo studies also reflect a 
similar correlation between TIMP-1 and MMP-9 expression. There was a higher 
expression of MMP-9 as shown by imunohistochemistry in the vehicle group compared 
to EPO treated or sham operated animals. This finding seems to contradict previous 
studies which showed that EPO increased MMP2/9 secretion into the media of 
endothelial cells (Wang L. et al). This apparent disparity could be explained by the 
difference in media and whole cell lysate. Additionally, endothelial cells make up a small 
proportion of brain tissue and thus would not impact total MMP-9 activity. In vivo 
inhibitions of either JAK-2 or TIMP-1 show a notable decrease in TIMP-1 expression 
(immunohistochemistry) even with EPO treatment which we also saw with our TIMP-1 
activity but not expression. Immunohistochemistry preserves protein structure and 
integrity thus allowing for continued interaction between the active site of TIMP-1 and the 
neutralizing antibody. However, during western blotting, the protein is run under 
denaturing conditions thus allowing for separation of the neutralizing antibody from the 
epitope. Thus it not surprising that visible TIMP-1 suppression was observed via 
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immunohistochemistry in the TIMP-1 neutralizing antibody group that was not seen in 
the western blot results. The interplay between EPO, TIMP and MMP appeared to be 
occurring primarily in neuron, whether this interaction is autocrine or paracrine is still to 
be elucidated. 
The mechanism by which EPO confers its neuroprotection is still unfolding. In 
2002, Ruscher et al observed that inhibition of the JAK/STAT pathway with 
pharmaceutical inhibitor AG490 abolished EPO’s neuroprotection in an in-vitro model of 
hypoxia ischemia (Ruscher et al. 2002). This was validated by our findings both in vitro 
and in vivo. However the reversal of EPO’s neuroprotection by inhibition of TIMP-1 that 
we observed was not previously shown in neuronal cell in vitro or in vivo. Thus, based 
on this observation we concluded that in addition to the activity of the JAK/STAT 
pathway TIMP-1 also plays a crucial role in EPO-induced neuroprotection in in-vivo and 
in vitro models of hypoxia ischemia. This finding provides important information for 
expanding our understanding of EPO as a potential treatment for neonatal hypoxic-
ischemic brain injury.  
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Abstract  
Erythropoietin (EPO), a hematopoietic growth factor, increases oxygen 
availability during hypoxia/ischemia and is associated with neuroprotection in: in vivo 
and in vitro models of hypoxia ischemia. Hypoxia inducible factor (HIF)-1α is the central 
transcriptional factor for regulation of oxygen associated genes in response to hypoxia. 
EPO a downstream gene of hypoxia inducible factor was shown to inhibit HIF-1α in a 
dose dependant manner in an in-vitro model of hypoxia ischemia. This study elucidates 
the key mediator of EPO-induced HIF-1 inhibition and subsequent neuroprotection.  
Oxygen and glucose deprivation was used to model hypoxia ischemia in vitro. Our 
findings showed that EPO treatment resulted in an increase in prolyl hydroxylase (PHD)-
2 transcription and translation, inhibition of HIF-1 expression, ROS formation and 
MMP-9 activity which resulted in neuroprotection. We also observed that EPO-induced 
neuroprotection was reversed by siRNA silencing of PHD -2. This led to the conclusion 
that PHD-2 is a key mediator of EPO-induced HIF-1 inhibition and subsequent 
neuroprotection in an in vitro model of hypoxia ischemia. 
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Abbreviations  
 
EPO: Erythropoietin  
HIF: Hypoxia Inducible Factor   
MMP: Matrix Metalloproteinase  
NGF: Neuronal Growth Factor  
OGD: Oxygen and Glucose Deprivation 
PHD: Prolyl Hydroxylase 
ROS: Reactive Oxygen Species  
VHL: Von Hippel Lindau 
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Introduction 
Stroke continues to be among the leading cause of mortality and morbidity; with 
ischemic strokes accounting for more than 75% of all incidents (ASA, AHA). Despite 
extensive stroke research there are few effective treatments available. Clinically, tissue 
plasminogen activator (tPA) is commonly used. However the therapeutic window for tPA 
is only three hours (Su et al., 2008).  Several animal studies have shown promising 
results for the use of stroke therapy however, recent clinical trials proved otherwise (Sun 
et al., 2005); (Ehrenreich et al., 2009). Thus it’s imperative that we determine the key 
mechanisms of EPO- induced neuroprotection. This will allow us to harness the 
beneficial effects EPO treatment while minimizing the detrimental effects EPO therapy. 
Cerebral hypoxia ischemia promotes an accumulation of hypoxia inducible factor 
(HIF)-1 in neurons. HIF-1- is innate modulator of oxygen homeostasis in most 
aerobes (Zagorska & Dulak, 2004). During conditions of hypoxia it initiates transcription 
of VEGF (Mu & Chang, 2003), erythropoietin (EPO)(Prass et al., 2003), glucose 
transporter-1 (GLU-1), glycolytic enzymes (Jones & Bergeron, 2001a), and several 
prosurvival genes. However HIF-1 also prompts the transcription of proapoptotic genes 
such as, MMP-9 (DeNiro et al., 2010), BNIP3(Bruick, 2003), Nix (Sowers et al., 2001), 
p53 and the caspases  (Li et al., 2005a).  
Under normoxic condition HIF-1 is continuously synthesized and degraded 
within 5 minutes by the ubiquitin–proteasome pathway (Huang et al., 1998; Kallio et al., 
1999; Salceda & Caro, 1997). HIF-1 first undergoes hydroxylation by prolyl hydroxylase 
(PHD)-2 which allows it to interact with the product of the von Hippel-Lindau (VHL) tumor 
suppressor gene (Ivan & Scaiano, 2003a; Jaakkola et al., 2001b; Lee et al., 2003). This 
interaction allows for the poly ubiquitination and proteasome-dependent degradation of 
HIF-1. 
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PHDs have a strikingly low O2 affinity which is ideal for oxygen sensing (Epstein 
et al., 2001d; Hirsila et al., 2003).  Reduced oxygen or increased ROS allows for the 
stabilization and accumulation of HIF-1 (Cash et al., 2007; Evans et al., 2005; Kamura 
et al., 1999; Lisztwan et al., 1999; Stebbins et al., 1999) .The absence of oxygen or the 
presence of ROS promotes the destabilization of PHD-2 (Cash et al., 2007a; Epstein et 
al., 2001; Evans et al., 2005; Jones & Bergeron, 2001). HIF degradation pathways 
require either hydroxylation or acetylation which is PHD-2 and oxygen dependant.  
HIF- target gene, EPO, has been shown to modulate other target genes of HIF-
1such as matrix metalloproteinases (MMPs), vascular endothelial growth factor 
(VEGF), cyclooxygenase (COX), nitric oxide synthase (NOS) and p53 (Wang et al., 
2008). However the effect of EPO on HIF-or its primary regulator PHD-2 warrants 
further investigation. EPO was shown to stabilize mitochondrial membrane potential and 
decrease ROS in Abeta(25-35)-induced neuronal toxicity in PC12 cells, up-regulated 
anti-apoptotic and down regulate pro-apoptotic proteins (Li et al., 2005b). Alternately 
ROS promotes HIF- accumulation. Therefore we hypothesized that EPO-induced 
neuroprotection will reduce HIF-1 accumulation during hypoxia ischemia in vitro by 
increasing PHD-2 and inhibiting ROS formation. We explored this hypothesis using 
oxygen and glucose deprivation (OGD) of NGF differentiated PC-12 cells to model 
cerebral hypoxia ischemia in vitro. The expression of HIF-1, HIF-2, PHD-2 and VHL, 
as well as the accumulation of ROS in the presence and absence of EPO treatment in 
during OGD were assessed. We then investigated if pharmacological inhibition of EPOR 
or siRNA silencing of PHD-2 increases ROS accumulation and negates EPO-induced 
neuroprotection during hypoxia ischemia in vitro. Neuroprotection was assessed by cell 
death.  
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Materials and Methods 
Materials 
The cell line (rat pheochromocytoma cells, PC-12 cells) and serum supplements 
were obtained from ATCC (Manassas, VA.). Human recombinant erythropoietin (Procrit 
©) was from Loma Linda University, Hospital Pharmacy (Loma Linda, CA.). Neuronal 
growth factor (NGF) was from Alomone Laboratories Ltd. (Jerusalem, Israel). Rat 
primary antibodies toward HIF-1 and HIF-2 were from ABD Serortec (Raleigh, NC). 
HIF-PHD-2 antibody, β−actin and all secondary antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Gelatin gel, TRIZOL reagent, and primers were from 
Invitrogen (Carlsbad, CA). Cell death ELISA was from Roche Diagnostics (Indianapolis, 
IN). All other reagents were obtained from Fisher Scientific (Tustin, CA). 
 
Methods 
Culturing and Differentiation of Cells 
Rat pheochromocytoma cells (PC-12 cells) (ATCC Manassas,VA) passage 6 
through 9 were be use. Cells were grown in Dulbecco’s modified Eagle's medium 
(DMEM)(Sigma Aldrich ST.Louis MO) with 5% Fetal bovine serum (FBS) and 10% horse 
serum (HS)(ATCC Manassas,VA), 1% Penicillin/streptomycin and 25mM glucose  as 
previously described (Greene, 1976).Cells were incubated in 5% carbon dioxide 
incubators at 37°C. At 75-80% confluence cells were sub-cultured on poly-L- lysine 
coated dishes (BD San Diego CA) and allowed to attach for 24 hours. Neuronal growth 
factor (NGF)(Alamones lab Israel) 50ng/mL was then added and cells allowed to 
differentiate. . Approximately 75% of media was replaced every 2-3   days until 60-70% 
of the cells were differentiated (Dickson et al., 1986). 
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Treatment of Cells 
Normal media was replaced with glucose-free, supplemented DMEM with either 
0 or 10 U/ml EPO. Cells were then placed in a hypoxic chamber with less than 1% 
oxygen for 2 hours (Agani et al., 2002). The media was then replaced with normal media 
and cell allowed to recover for 18 hours. Cells were then collected for cell death assay, 
western blotting, gelatin zymography or reverse transcriptase polymer chain reaction 
(RT-PCR).  
  
Protein extraction from PC-12 cells  
Protein was extracted as previously described (Andrews and Faller 1991). 
Briefly, cells were detached by scraping, rinsed with cold PBS, centrifuged and 
supernatant discarded. Two hundred  μL of radio-immuno-precipitation assay (RIPA) 
lysis buffer [20 mM Tris, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% Na deoxycholate, 1 mM 
EDTA, and 0.1% sodium dodecyl sulfate (SDS)] supplemented with protease and 
phosphatase inhibitor cocktails (Sigma-Aldrich, St. Louis, MO) were added and the 
suspension shaken for 15 minutes at 4°C followed by centrifugation. Protein 
concentrations were estimated by Bradford Assay (BioRad, Hercules, CA). Samples not 
used immediately were aliquoted stored at -80°C for later use. 
 
Transfection 
Cells were transfected Silencer® selected pre-designed siRNA to HIF-PHD-2 
using Lipofectamine TM reagent according as previously described (Lee et al., 2008). 
Briefly 24 hours prior to transfection cells were trypsinized and plated at a density of 2 
x105 cells in polly D-lysine coated 6 well plates (BD biosciences) with Opti-MEM® 
reduced serum media. Plus reagent and siRNA were allowed to incubate for 15 minutes 
in a 1:1 ratio.   Lipofectamine TM LTX reagent was then added and mixture incubated for 
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25 minutes at room temperature. Reduced serum media was removed from cells and 
replaced with media containing 5nMconcentration of siRNA complexed with 
Lipofectamine TM. Plates were incubated for 24 hours and transfection efficiency 
assessed and cells used for experiments. 
 
Western Blotting 
SDS-PAGE electrophoresis was done as previously described (Dominguez et al. 
2008).  A 40ug sample of total protein per well with a 1:1 ratio of sample buffer was 
denatured at 95°C for 3-5 min prior to loading 4-12% Bis Tris gel (Bio Rad). Gels were 
electrophoresed and protein transferred to nitrocellulose membrane. The membranes 
were blocked with nonfat blocking grade milk (Biorad) and probed with the appropriate 
dilutions of primary to HIF-1 (Abcam), HIF-2 (ABD Serotec), PHD-2 (Santa Cruz 
Biotechnology, Santa Cruz, CA.), VHL (cell signaling Technologies) or loading control -
actin (Santa Cruz Biotechnology). Membranes were washed and protein visualized using 
ECL Plus, Chemiluminescence (GE Healthcare and Life Sciences, Piscataway, NJ). The 
optical densities of the bands were calculated with Image J, version 1.0 and normalized 
to β-actin which was used as a loading control for all proteins studied. 
 
Gelatin Zymography  
Gelatin zymography was performed as previously described (Tang et al. 2004; 
Wang et al. 2000; Wu et al. 2010). Briefly, 60 μg samples of protein extract were 
prepared and separated by electrophoresis in 10% Tris-glycine gel with 0.1% gelatin as 
substrate (Bio-Rad, Hercules, CA). The gel was re-natured for one hour and then 
incubated with development buffer at 37°C for 48 hours. After development, the gel was 
stained with 0.5% coomassie brilliant blue R-250 for one hour and then destained for 18 
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to 24 hours. MMP activity was visualized and photographed with BioRad Versa Doc 
imager. Optical densities were calculated with Image J (version 1.0) software.  
 
Assessment of Reactive Oxygen Species Formation 
ROS was assessed immediately after OGD using OxiSelect™ ROS Assay Kit 
(Cell Biolabs Inc. San Diego CA). The assay used 2, 7-Dichlorodihydrofluorescin 
diacetate (DCFH-DA) and was performed according to manufacturer’s protocol. Briefly 
cell were washed with Dulbecco’s phosphate buffer saline (DPBS) and incubated 1mM 
of DCFH-DA in serum free media for 1 hour. Media was discarded and cells washed with 
DPBS to remove unabsorbed DCFH-DA. DCF was then evaluated by spectrophotometry 
at wavelength 405 nm and reference wavelength in a 96 well plate reader (BioRad, 
Hercules CA).  
 
Reverse Transcriptase Polymerase Chain Reaction 
RNA was extracted using TRIZOL reagent (Invitrogen). DNA was synthesized 
using SuperScript® First-Strand Synthesis System for RT-PCR (Invitrogen). PCR for 
HIF-1, PHD-2, VHL and internal standard GAPDH was performed with using the 
following primers (forward 5’GGCTTTGTTATGTGCTAAC3’ and reverse 
5’ACTTGATGTTCATCGTCCTC3’ for HIF-1), (forward 
5’TAAACGGCCGAACGAAAGC3’ and reverse 5’GGGTTATCAACGTGACGGACA3’ for 
PHD-2), (forward 5’ACAGGATGTGCAAGGACAAGTG3’ and reverse 
5’TAGTCTGCAGCATTCCGTGAGT3’ for VHL) and (forward 
5’ACCACAGTCCATGCCATCAC3’ and reverse 5’TCCACCACCCTGTTGCTGTA3’ for 
GAPDH). Samples were cycled using a 2720 thermal cycler (Applied Biosciences).The 
samples were denatured at 95°C for 5 minutes followed by 30 samples of amplification 
for HIF-1, PHD-2 and VHL and 25 cycles for GAPDH. The amplication cycle consisted 
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of 30 seconds denaturation at 94°C 30 seconds annealing at 56°C, 1 minute extension 
at 72°C and a final extension of 5 minutes at 72°C. Samples were electrophoresed on 
2% agarose gel with 0.5ug/mL etidium bromide.  Gels were visualized under UV light 
and photographed, and optical densities of the bands were analyzed with Quantity One 
software (Bio-Rad). 
 
Cell Death Assessment 
Cell death was also determined using an Cell Death ELISA kit from Roche 
Diagnostics (Indianapolis, IN) according to manufacturer’s instruction. Briefly the 
supernatant of lysed cells was conllected and the concentration of mono- and 
oligonucleosomes present in whole cell lysate using an ELISA kit. The concentration 
was determined by spectrophotometry at wavelength 405nm with a reference 
wavelength of 495nm using a 96 well plate reader (BioRad, Hercules CA). 
 
Statistical Analysis  
Data are presented as mean ± standard deviation. All data were validated using 
one way ANOVA followed by Tukey or Dunn’s test. Statistical evaluation was performed 
using Sigma Stat software version 3.5 (DUNDAS software LTD. Germany). 
 
72 
Results 
Determining if both HIF-1 and HIF-2 are Inhibited by EPO 
Treatment 
To determine if the reduction of HIF-1 expression we observed was a result of 
an upregulation of HIF-2, we evaluated the expression of both HIF-1 and HIF-2 
following OGD in NGF-differentiated PC-12 cells. HIF-1 expression was significantly 
lower (p<0.5) in EPO treated cells compared to untreated cell figure 3.1.B. However HIF-
2 expression remained relatively unchanged via EPO treatment figure 3.1.C. Thus, 
suggesting that HIF-1 is the more prevalent HIF during OGD in PC-12 cells. 
Consequently a significant increase (p< 0.5) in PHD-2 expression was also observed in 
the EPO treated group compared to normoxic and untreated group. 
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Figure 3.1. The profile of HIF-1, HIF-2, and PHD-2 following 2 hours of OGD. (A)  
A representative image of a western blot of HIF-1, HIF-2, PHD-2 and the -actin as 
the loading control  (B) Densiometric quantification of HIF-1  expression.  (C) HIF-2 
expression following EPO treatment. (D) PHD-2 expression following OGD. Data 
represent mean (± SD) n=6 in all groups. *P<0.05 compared to 10U/ml EPO treated 
group. HIF-1 but not HIF-2 expression was altered in the presence of EPO treatment.  
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The Profile of the Extracellular (media) pH and Electrolytes Following 
OGD 
To determine if the change in HIF-a expression was mediated by a change in pH 
and electrolytes we evaluated the pH, calcium and potassium of the media.We 
hypothesized that intracellular changes in pH and electrolytes would be reflected in the 
media since it is an artificial representation of the extracellular fluid. The pH was 
unaffected by either OGD or EPO treatment figure 3.2.A. OGD prompted an increase in 
extracellular calcium which was unaltered by EPO treatment figure 3.2.B. Hypoxia also 
led to a modest increase in extracellular potassium in all groups except 10U/mL EPO 
and control siRNA. Thus 10U/mL EPO treated group was significantly (p<0.05) higher 
than normoxia but significantly lower (p<0.05) that all other groups except control siRNA 
group figure 3.2.C. 
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Figure 3.2. The pH, calcium and potassium content in the media following OGD. 
(A) The pH of the media following 2 hours OGD with and without EPO treatment. (B) The 
calcium present in the media following 2 hours OGD with and without EPO treatment. 
(C) The calcium present in the media following 2 hours OGD with and without EPO 
treatment. Data represent the mean and (± SD) n=6 in all groups. *P<0.05 compared to 
10U/ml EPO treated group. #P<0.05 compared to normoxia. EPO treatment had no 
effect on media pH or calcium. 
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The Effect of EPO and PHD-2 Inhibition on ROS Formation and HIF-
1 and PHD-2 Expression 
The primary mediators of HIF- expression are ROS and hypoxia. Therefore we 
determined the consequence of EPO treatment on ROS formation in the presence of an 
EPOR-Fc chimera which competitively binds to EPO thereby preventing it interaction 
with the naïve EPOR and a PHD-2 siRNA. Transfection increases the porusness of the 
cell membrane and is of itself an form of injury thus its not surprising that the basal levels 
in the siRNA control group is higher that that of the untreated groups. The formation of 
ROS was enhanced during OGD in all groups except the 10U/mL group and the control 
siRNA +EPO group figure 3.3.B.  Accordingly HIF-1 expression was positively 
correlated with ROS formation. Elevated in all of the groups exhibiting high ROS 
(p<0.05) and decreased in EPO treated groups figure 3.3.C. Conversely PHD-2 
expression was inversely correlated with ROS formation and HIF-1 expression. PHD-2 
expression was notably increased in 10U/mL group (p<0.05) and compared to 
untreated, EPOR-Fc chimera, control siRNA, PHD-2 siRNA and PHD-2 siRNA + EPO 
figure 3.3.D. This suggests that EPO either directly or indirectly alters ROS formation, 
HIF-1 and PHD-2 expression when used with NGF-differentiated PC-12 cells.  
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Figure 3.3. ROS formation, HIF-1 and PHD-2 expression in the presence of EPO 
and PHD-2 inhibition. (A) Shows a representative blot of HIF-1, PHD-2 and the 
loading control -actin. (B) ROS formation during OGD in the presence of inhibitors. (C) 
HIF-1expression after OGD in the presence of inhibitors. (D) PHD-2 expression in after 
OGD in the presence of inhibitors. Data represent the mean and (± SD) n=6 in all 
groups. *P<0.05 compared to 10U/ml EPO treated group. Inhibition of EPO or PHD-2 
enhanced HIF-1 expression and ROS formation  
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Determining the Effects of EPO Treatment on mRNA Levels of HIF-
1, PHD-2 and VHL 
Changes in protein expression are not always indicative of transcriptional 
changes. Thus to determine if the changes we observed in HIF-1 and PHD-2 
expression with EPO treatment and inhibitor were at the transcription or the translational 
levels we did RT-PCR for these protein figure 3.4. Silencing of PHD-2 via siRNA 
triggered a significant increase (p<0.05) in HIF-1transcription compared to 10U/mL 
EPO group. On the contrary competitive inhibition of EPO did not affect HIF-1 
transcription with and without EPO treatment figure 3.4.B.  Alternately either inhibition of 
EPOR or silencing of PHD-2 significantly lowered mRNA levels of PHD-2 figure 3.4.C. 
Downstream effecter of HIF-1 degradation VHL appeared unaffected by EPO treatment 
as well as inhibition of EPO or PHD-2, figure 3.4.E. This observation alluded to PHD-2 
as one of the primary effecter of HIF-1 inhibition and subsequent neuroprotection in 
NGF-differentiated PC-12 cells. 
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Figure 3.4. mRNA levels of HIF-1, PHD-2 and VHL in the presence of EPO and 
PHD-2 inhibition. (A) Shows representative gel of HIF-1, PHD-2 and the 
housekeeping gene gapdh. (B) HIF-1 mRNA expression after OGD in the presence of 
inhibitors. (C) PHD-2 mRNA expression in after OGD in the presence of inhibitors. (D) 
Shows representative gel of VHL and the housekeeping gene gapdh. (E) VHL mRNA 
expression after OGD in the presence of inhibitors. Data represent the mean and (± SD) 
n=6 in all groups. *P<0.05 compared to 10U/ml EPO treated group. Inhibition of PHD-2 
enhanced HIF-1 transcription in the presence and absence of EPO.  
. 
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Inhibition of EPO or PHD-2 alters MMP-9 Activity and Reversed 
EPO’s Neuroprotection 
Downstream molecule of HIF-1, MMP-9 is associated with exacerbated injury 
and cells death in the acute stages of hypoxia. Thus to determine if EPO-induced HIF-
1 inhibition affects downstream genes expression and subsequent cell death we 
assessed MMP-9 activity and cell death. According to expectations EPO treatment was 
associated with lower MMP-9 activity. However inhibition of PHD-2 rapidly reversed this 
resulting in significantly higher level of MMP-9 activity in PHD-2 siRNA + EPO group 
compared to 10U/mL EPO and control siRNA + EPO figure 3.5.B. Alternately EPOR-FC 
chimera did not appear to negatively affect MMP-9 activity in the presence of EPO.  
Consequently cell death was positively correlated with MMP-9 activity. Inhibition of EPO 
or PHD-2 in the presence of or absence of EPO treatment visibly reversed EPO-induced 
neuroprotection compared to 10U/mL (p<0.05) EPO figure3.5.C.   
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Figure 3.5. The effects of EPO treatment on MMP-9 activity and subsequent cell 
death after OGD. (A) Shows representative gel of MMP-9 activity (light bands). (B) 
Densiometric quantification of MMP-9 activity as detected via gelatin zymography. (C) 
Shows cells death assessment via ELISA. Data represent the mean and (± SD) n=6 in 
all groups. *P<0.05 compared to 10U/ml EPO treated group. #P<0.05 compared to 
untreated. Inhibition of PHD-2 significantly increased MMP-9 activity and cell death with 
and without EPO.  
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Discussion 
Our findings showed that EPO-induced inhibition of HIF-1 which was associated 
with elevated transcription and translation of PHD-2. Inhibition of EPO had prompted an 
increase in HIF-1 protein expression but had no effect on mRNA. EPO-induced 
elevation of PHD-2 was coupled with reduced ROS formation, MMP-9 and cell death. 
HIF-1 and-2 shares 40% homology. HIF-2 has been shown to bind to the 
beta subunit of HIF-1during hypoxia (Krieg et al., 2000). An accumulation of HIF-1 or 
HIF-2 during hypoxia is tissue dependant.  The specific HIF in neuronal tissue is still 
highly debate (Yeo et al., 2008). However in our study a profile of both HIFs revealed 
that, HIF-2 protein expression in cells was relatively unchanged during OGD with or 
without EPO treatment. This inferred that HIF-1 and not HIF-2 is the primary HIF 
associated with hypoxia in NGF differentiated PC-12 cells. On the contrary HIF-1 was 
notably increased by OGD and diminished with EPO treatment. Reduction of HIF-
1protein expression by the administration of exogenous EPO was not previously 
shown and thus warranted further investigation. EPO is a downstream gene of HIF-1 
(Semenza, 1998).Therefore; we speculated that the apparent EPO-induced inhibition of 
HIF-1 was probably caused by a negative feedback inhibition. However a profile of the 
primary regulators of HIF-1 degradation, PHD-2 and ROS alluded to a much more 
complex mechanism. 
PHDs are oxygen sensors that use oxygen as a co-substrate and 2-oxoglutarate 
and iron as cofactors.  Because of the iron dependence iron compounds could be used 
for hypoxic mimicry (Cioffi et al., 2003; Lieb et al., 2002). PHDs are extremely sensitive 
to low O2 concentration which is ideal for oxygen sensing (Epstein et al., 2001b; Hirsila 
et al., 2003b). They are dioxygenases that catalyze oxygen-dependent hydroxylation of 
HIF-1α prolyl residues. PHD-2 promotes the degradation of both HIF-1and HIF-2 
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(Chang et al., 2005). Thus it was not surprising when we observed an inverse correlation 
between HIF-1 and PHD-2 protein expression after hypoxia (figure 3.1. and figure 3.3) 
and a marked increase in ROS formation that mirrored HIF-1 expression. Our data 
corroborated published reports that, reduced oxygen or increased ROS allows for the 
stabilization and accumulation of HIF-1 (Cash et al., 2007b; Evans et al., 2005b; 
Kamura et al., 1999b; Lisztwan et al., 1999b; Stebbins et al., 1999b) .  Low levels of 
oxygen or high levels of ROS promotes the destabilization of PHD-2 (Cash et al., 2007c; 
Epstein et al., 2001a; Evans et al., 2005a; Jones & Bergeron, 2001b). However contrary 
to our expectation there were no notable changes in extracellular pH or electrolytes: 
Ca2+ and K+. Despite this observation we are unable to say conclusively that EPO-
induced inhibition of HIF-1 is independent of electrolytes regulation, because it is 
possible that the change were too small to be detected in the media. Studies have 
shown that prolyl hydroxylation and acetylation, modulates cellular HIF-1 levels by 
governing the physical interaction between HIF-1α and VHL. VHL binds with elongin B, 
elongin C, Rbx1 and Cul2 to form the E3 ubiquitin ligase. The ubiquitin is unable to bind 
HIF-1 during hypoxia because HIF-1lacks hydroxylation or acetylation at this time 
(Ivan & Scaiano, 2003b; Jaakkola et al., 2001a). Thus, we anticipated that EPO-induced 
inhibition of HIF-1 would reflect corresponding increase in regulatory proteins PHD and 
pVHL expression but would not alter mRNA levels. On the contrary pVHL protein 
expression was almost undetectable in all groups (data not shown) and is therefore 
inconclusive. HIF-1 protein but not mRNA levels were significantly reduced by EPO 
treatment. This suggests that EPO-induced inhibition of HIF- is not a direct action at the 
transcriptional level. Thus changes in HIF-1protein expression was mediated by either 
physical interaction of EPO with HIF-1 or by transcriptional regulation of a HIF-1 
regulator. Thus, we were not surprised when we observed that EPO treatment 
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propagated increased in both transcriptional and translational levels of PHD-2. This 
alluded to modulation of PHD-2 levels as the primary mechanism by which exogenous 
EPO inhibits HIF-1 in NGF differentiated PC-12 cells during hypoxia ischemia which is 
associated with neuroprotection. Conversely Ratan and colleagues showed that 
inhibition of PHD and activation HIF-1 was associated with neuroprotection in vivo and 
in vitro (Ratan et al., 2008; Lee et al., 2009; Siddiq et al., 2009). The apparent 
contradiction in these reports attests to the biphasic nature of HIF-1 which can be 
beneficial as well as detrimental (Calvert et al., 2006; Halterman & Federoff, 1999; Leker 
et al., 2004). The dichotomy of HIF-1neuroprotection is best explained by Baranova 
and colleagues who described an oscillation of HIF-1 levels following hypoxia ischemia. 
Transient increases in HIF-1 within the first 24 hours after an injury was associated with 
elevation of proapoptotic genes however, downstream prosurvival  genes of HIF-1 
were upregulated with later (>24hrs)  sustained elevation of HIF-1(Baranova et al., 
2007) . Thus HIF-1 is detrimental in the acute stages of injury but beneficial in the 
delayed/recovery stage of injury.  
Silencing of PHD-2 prompted a notable increase in both protein and mRNA 
levels of HIF-1, MMP-9 activity and resultant cell death even in the presence of EPO 
treatment. These observations lends to the conclusion that PHD-2 is a potent mediator 
of EPO-induced neuroprotection in NGF differentiated PC-12 cells.  
Given the direct or indirect interaction of EPO with biphasic HIF-1 and its 
primary regulator PHD-2 caution should be exercised to harness the beneficial 
neuroprotective effects of EPO, without triggering the detrimental effect of delayed 
inhibition of HIF-1.  
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CHAPTER FOUR 
DISCUSSION AND CONCLUSION 
 
Summary/Highlight of Findings 
Our findings show that EPO-induced neuroprotection was mediated by both 
upregulation of TIMP-1 and inhibition HIF-1α.  This finding was supported by the 
following observations: (1) EPO-induced neuroprotection was associated with increased 
phosphorylation of the JAK-2 receptor, downstream signal transducer STAT-3 and its 
transcription product TIMP-1 and significantly lower MMP-9 activity in: in vivo and in vitro 
models of hypoxia ischemia. (2) Inhibition of either JAK-2 or TIMP-1 reversed the 
protective effects of EPO in both models. (3) The pharmacological inhibition of JAK-2 or 
TIMP-1 was associated with reduced expression of STAT-3 and downstream gene, 
TIMP-1 activity and considerable increase in MMP-9 activity. (4) HIF-1 expression and 
ROS accumulation were significantly reduced following EPO treatment in OGD cells. (5) 
EPO- induced inhibition of HIF-1 was associated with increased PHD-2 expression and 
a corresponding decrease in ROS formation, MMP-9 activity and cell death.  
 
The State of the Field Prior to this study 
Currently it is believed that EPO –induced neuroprotection is mediated by three 
major pathways downstream of JAK-2 phosphorylation namely: STAT-5, PI3K/AKT and 
MAPK/RAS/ERK1/2 pathways (Ruscher et al., 2002; Socolovsky et al., 1999; Ribatti et 
al., 1999; Shen et al., 2010). Previous studies have shown that JAK-2 phosphorylated 
STAT -5 which is then translocated to nucleus where it activates the gene transcription 
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of several proapoptotic genes suchas Bcl-xL and the X-linked inhibitor of apoptosis 
protein (XIAP) (Socolovsky et al., 1999). The newly transcribed anti apoptotic proteins 
inhibits both caspase dependent and caspase independent cell death, by modulating 
caspase 8,3 and 9 activation as well as cytochrome c transport from the mitochindria 
(Siren & Ehrenreich, 2001; Siren et al., 2001b; Siren et al., 2001a). EPO bounded to 
EPOR modulates calcium-calmodulin interation resulting in a calcuim influx into the cells 
(Kakihana et al. 2005). Increased intracellular calcium activates the PI3K/AKT pathway. 
Prosurvival protein XIAP, Bcl2 and BclxL downstream is upregulated while proapoptotic 
proteins Bad and caspase 9are downregulated via PI3K/AKT activation, thereby 
promoting neurrroprotection (Dhanasekaran et al., 2008). The third major pathway that is 
know to play a role in EPO-induced neuroprotection is the RAS/MAPK/ ERK1/2 pathway. 
Activated EPOR phosphorylates Ras which binds to c-Raf to phosphorylate MAP2 
lending to the phosphorylation of ERK1/2 which in turn activates MAPK. MAPK 
subsequent inhibits Bax translocation form the cytosol and promotes Bcl-2 transcription 
leading to cell survival and proliferation  (Arai et al., 2002; Morrison et al., 2002). Tables 
4.1 and 4.2 summarized what was known in the field prior to our study.  
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Table: 4.1. A Summary of Erythropoietin-induced Neuroprotection in Animal Models of Ischemic Stroke 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Stroke 
Model Species 
Time of 
Administration Outcome Measured Effect Reference 
Focal  
Ischemia 
Male 
Long 
Evans 
Rats 
6, 7 and 8 days 
after occlusion 
Neurobehavior 
 Lesion Volume, Tissue 
Loss 
Improved infarct volume and 
neurological outcomes 
Belayev et al. Brain 
Res. 2009 Jul 
14;1280:117-23.  
Male 
C57BL/6 
mice 
30 minutes 
before 
ischemia/ daily 
for 3, 7, 14 and 
21 days 
Infarct Volume. 
Angiogenesis. Endothelial 
Cell Survival. Local 
Cerebral Blood Flow 
(LCBF). Apoptosis : 
Caspase activities 
Decrease cell death and infarct 
volume 3 days after stroke. 
Restored CBF 14 days after 
stroke. neurovascular protection 
and neurogenesis  
Li et al. J Cereb 
Blood Flow Metab. 
2007 
May;27(5):1043-54 
Global 
Ischemia 
Male 
Sprague-
Dawley 
Rats 
20 hr before or 
20 min or 1 hr 
after ischemia 
Histology of neurons.  Cell 
Death: DNA Fragmentation 
Protected CA1 neurons of 
hippocampus. Decreased 
neuronal death 
Zhang et al. J 
Neurosci Res. 
2006 May 
15;83(7):1241-51. 
Male 
Mongolia
n Gerbils 
Immediately 
after  
restoration of 
blood flow 
Brain Edema. Hippocampal 
neuronal death. Brain nitric 
oxide. Survival 
Increased neuronal survival and 
decreased brain edema. 
Reduced NO levels after 
ischemia 
Calapai et al. Eur J 
Pharmacol. 2000 
Aug 11;401(3):349-
56. 
Neonatal 
Hypoxia 
Ischemia 
P-7  
Sprague-
Dawley 
Rats 
24 hours after 
insult 
Inflammatory effects. Brain 
Weight.  
Attenuated brain injury Reduced   
inflammatory cytokine and 
leukocytes infiltration. 
Sun et al. Stroke. 
2005 
Aug;36(8):1672-8. 
P-7  
Sprague-
Dawley 
Rats 
20 minutes 
after insult/ Day 
2,4 and 6 
Infarct Volume. 
Revascularization. 
Neurogenesis. 
Immunohistochemistry 
Neurological behavior 
Reduced tissue infarct volume. 
Enhanced  revascularization, 
increased sub-ventricular zone 
cell proliferation and neuronal 
migration. Improved neurological 
outcomes 
Iwai et al. Stroke. 
2007 
Oct;38(10):2795-
803 
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Table: 4.2 A Summary of Erythropoietin-induced Neuroprotection in Animal Models of Hemorrhagic Strokes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stroke 
Model Species 
Time of 
Administration Outcome Measured Effect References 
ICH 
Male 
Sprague-
Dawley 
Rats 
5 minutes after 
surgery/ Daily for 
14 days 
Neurobehavior: 
Histopathological 
Computation of Tissue 
Loss, 
Immunohistochemistry for 
NeuN positive cells  
Significantly Improved Neurobehavior 
1 week after insult. Reduced injury 
and preservation of parenchymal 
cytoarchitecture. 
Grasso et al. 
Neurosurgery. 
2009 Oct; 
65(4):763-9 
Male 
Sprague-
Dawley 
Rats 
2 hours after 
surgery / Daily 
for 1 or 3 days 
Neurobehavior: 
Hemorrhage Volume. 
Hemispheric Atrophy. 
Brain Edema. Cell Death: 
TUNEL staining, Caspase 
Activity 
Better functional recovery. Reduced 
brain water content. Decreased mean 
hemorrhage volume and hemispheric 
atrophy. Reduced apoptosis: lower 
caspase activities, TUNEL positive 
cells  
Lee et al. J 
Neurochem. 
2006 
Mar;96(6):1728-
39 
SAH  
Male New 
Zealand 
White 
Rabbits 
5 minutes after 
SAH induction/ 
every 8 hrs for 72 
hrs 
Neurobehavior: 
 Ischemic Lesions. 
Analysis of Basilar Arteries 
diameter 
Improved neurobehavioral outcome. 
Decreased ischemic neuronal 
damage. Reduced vasoconstriction of 
arteries 
Grasso et al. 
Proc Natl Acad 
Sci USA. 2002 
Apr 
16;99(8):5627-
31. 
Male New 
Zealand 
White 
Rabbits 
* Immediately 
after injection of 
autologous 
blood.  
Cerebral Angiography. 
Vascular Reactivity.  
Reduced cerebral vasospasm. 
Augmented basilar arterial relaxation 
to acetylcholine 
Santhanam et al. 
Stroke. 2005 
Dec;36(12):2731-
7 
Male New 
Zealand 
White 
Rabbits 
10 minutes after 
SAH procedure/ 
Day 2, 4, and 6 
Computed tomography 
perfusion. CT angiography. 
Neurological Function. 
Histology 
Improved neurological outcomes. 
Improved cerebral blood flow and 
microcirculatory flow. Improved tissue 
perfusion 
Murphy et al. J 
Neurosurg. 2008 
Dec;109(6):1155-
64. 
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How does our finding advance the field?  
The current knowledge in the field allowed for for the use of erythropoietin in 
clinical trials as neuroprotective agent in stroke therapy. However erythropoiesis, 
coagulation and thrombosis were observed in some of the adult patients in one of the 
primary large center clinical trial using high dose EPO over a three week period 
(Ehrenreich et al., 2009). The adverse effects observed in that aforementioned study led 
many veteran EPO researchers to ask is there a future for EPO in stroke therapy 
(Minnerup et al., 2010)? In an attempt to   answer the aforementioned question we 
arrived at our study.  The key mediators of EPO induced neuroprotection in vivo and in 
vitro. Our findings showed that the modulation of TIMP-1, HIF-1, PHD-2 and MMP-9 
are the primary modalities of EPO-induced neuroprotection. This information will prove 
invaluable in prescribing EPO for stroke therapy. TIMP-1 is a prosurvival protein that is 
critical for cell survival but could promote excessive proliferation of cells if over-
expressed for long periods of time as was observed in cancer. The biphasic master 
regulator HIF-1 has both beneficial and detrimental properties. Thus extended inhibition 
of HIF-1 is also detrimental. Additionally MMP-9 is a major player in angiogenesis 
which is a critical part of wound healing. Because all of the primary mediators of EPO-
induced neuroprotection are biphasic the dose and time of administration of EPO are 
critical to its use in stroke therapy. Thus our response to Minnerup question is that there 
is a future for EPO in stroke therapy if used in moderation at modest doses for acute 
administration. The figure below integrated our findings into the current body of know on 
the mechanism of EPO-induced neuroprotection in stroke therapy.  
 94 
 
 
 
 
 
 
Figure 4.1. Schematic representation of how our findings fit into the current 
knowledge of the signaling pathways involved in EPO-induced neuroprotection.  
The primary mechanism of secondary injury due to hemorrhagic strokes is presented in 
blue. One of the primary mechanism of ischemic injury in presented in red. Matrix 
metalloproteinase serves as the pivotal molecule leading to pathology in both 
hemorrhagic and ischemic strokes. The green, grey and tan lines show the known 
signaling pathway activated downstream of Janus Kinase 2, prior to our study. The black 
lines show the signaling pathway we elucidated during this study.  
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Summary/Conclusion 
One of the key mechanisms of EPO-induced neuroprotection in hypoxia ischemia 
in vivo and in vitro is the upregulation of TIMP-1 and inhibition of HIF-1. EPO induced 
an upregulation of TIMP-1 via the JAK-2/STAT-3 pathway. The upregulated TIMP-1 
inhibited MMP-9 thereby conferring neuroprotection. Additionally EPO also triggered an 
increase in PHD-2 transcription and translation which lead to inhibition of HIF-1 protein 
expression.  The primary mediators of EPO-induced neuroprotection are STAT-3, TIMP-
1 and PHD-2. These molecules appear to signal from two divergent pathways that 
converge at the point of MMP-9. The common denominator in both pathways, MMP-9, is 
a biphasic zymogen that is detrimental during acute injury but critical in wound healing. 
Thus EPO-induced neuroprotection could be a double edged sword beneficial or 
detrimental depending on the dose and time of administration. However the benefits of 
EPO treatment in stroke therapy are tremendous and gravely outweigh the adverse side 
effects of coagulation and thrombosis. Therefore, EPO should be used with cautious 
optimism.   
 
Prospective 
To develop an EPO analog that lacks erythropoietic function. Dissociating the 
non-hematopoietic function of EPO from the hematopoietic function for treatment of 
stroke has proven to be challenging. Thus recent efforts have been made to design 
pharmaceutical analogs that lack the ability to initiate erythropoiesis. Structural analogs 
asialoerythropoietin and carbamylated-Epo (CEPO) both confers cellular survival and 
proliferation with minimal erythropoiesis (Erbayraktar et al., 2003; Leist et al., 2004; 
Adembri et al., 2008). These analogs appear to promote neuroprotection without 
initiating notable erythropoiesis, coagulation and thrombosis at low doses and for short 
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duration. However if the derivatives are able to withstand long treatment without the 
significant side effects is still to be elucidated.  Should I expand on my current study I 
would elucidate the ability of EPO analog CEPO to confer neuroprotection at high doses 
for extended duration and the mechanism of the proposed neuroprotection.   
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